var title_f1_40_1664="Water soluble vitamins A";
var content_f1_40_1664=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F77100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F77100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Chemical structure of vitamins B1, B2, B6 and B12",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 579px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_40_1664=[""].join("\n");
var outline_f1_40_1664=null;
var title_f1_40_1665="Acetic acid mag Endosc1";
var content_f1_40_1665=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Magnification endoscopy in a patient with Barrett's esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 441px; height: 232px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Magnification endoscopy following instillation of acetic acid in a patient suspected of having short-segment Barrett's esophagus (left panel). The magnified image (right panel) shows a reticular mucosal pattern sugestive of cardiac epithelium (rather than intestinal metaplasia), which was confirmed on pathology.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Moises Guelrud, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_40_1665=[""].join("\n");
var outline_f1_40_1665=null;
var title_f1_40_1666="Lymphangioleiomyomatosis CT I";
var content_f1_40_1666=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69954&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69954&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lymphangioleiomyomatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lymphangioleiomyomatosis in a 42-year-old woman. Multiple small cysts permeate the entire lung parenchyma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_40_1666=[""].join("\n");
var outline_f1_40_1666=null;
var title_f1_40_1667="Patient information: Managing loss of appetite and weight loss with cancer (The Basics)";
var content_f1_40_1667=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16248\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/38/42598\">",
"         Foods with fiber",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/22/29024\">",
"          Upper digestive tract",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?9/5/9299\">",
"         Patient information: Diarrhea in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/51/35634\">",
"         Patient information: High-fiber diet (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/36/579\">",
"         Patient information: Managing pain when you have cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/57/28562\">",
"         Patient information: Nausea and vomiting in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/16/37121\">",
"         Patient information: What are clinical trials? (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/4/29762\">",
"         Patient information: When your cancer treatment makes you tired (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?35/29/36308\">",
"         Patient information: Acute diarrhea in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?8/39/8817\">",
"         Patient information: High-fiber diet (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/managing-loss-of-appetite-and-weight-loss-with-cancer-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H14856194\">",
"      <span class=\"h1\">",
"       What can cause me to lose weight or have no appetite?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can lose weight or have no appetite because of your:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Cancer &mdash; Even if you eat a lot, your cancer might keep your body from taking in all the nutrients it needs.",
"       </li>",
"       <li>",
"        Treatments &mdash; Treatments such as chemotherapy, radiation, and medicines have side effects that can make it hard to eat. For example, these treatments can cause nausea, vomiting, mouth sores, dry mouth, or changes in taste and smell.",
"       </li>",
"       <li>",
"        Mood &mdash; Feeling sad or worried can make people lose their appetite.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14856201\">",
"      <span class=\"h1\">",
"       Why is it important to eat enough?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It&rsquo;s important to eat enough so that you stay as healthy and strong as possible, especially during your cancer treatment. Eating enough and getting enough fluids will also give you more energy and help you feel better in general.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14856208\">",
"      <span class=\"h1\">",
"       What foods can help keep my weight up?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Eating foods with a lot of calories and protein in them can help keep your weight up. Some examples of these foods are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Thick soups",
"       </li>",
"       <li>",
"        Milk, milkshakes, cheese, pudding, and smoothies",
"       </li>",
"       <li>",
"        Nutritional supplement drinks, such as Ensure&copy;, Boost&reg;, or Carnation&reg; Instant Breakfast",
"       </li>",
"       <li>",
"        Eggs, chicken, lean red meat, and fish",
"       </li>",
"       <li>",
"        Yogurt, frozen yogurt, and ice cream",
"       </li>",
"       <li>",
"        Peanut butter, nuts, dried fruit, and granola bars",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14856215\">",
"      <span class=\"h1\">",
"       What can I do on my own to eat enough?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To eat enough and make sure that your body gets the nutrients it needs, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Eat 5 to 6 small meals a day, instead of 3 large meals",
"       </li>",
"       <li>",
"        Eat healthy snacks whenever you feel hungry",
"       </li>",
"       <li>",
"        Add butter, oil, nuts, gravy, powdered milk, or cream to your foods to give them extra calories and protein",
"       </li>",
"       <li>",
"        Drink between meals instead of with your meals, so that you don&rsquo;t fill up on liquids",
"       </li>",
"       <li>",
"        Eat foods that smell good, or add spices or condiments to your food",
"       </li>",
"       <li>",
"        Eat with family or friends",
"       </li>",
"       <li>",
"        Buy pre-cooked foods or cook food ahead of time and freeze it",
"       </li>",
"       <li>",
"        Ask someone to cook or shop for you, if you are unable to cook or shop",
"       </li>",
"       <li>",
"        Take a short walk about an hour before you eat to help you work up an appetite",
"       </li>",
"       <li>",
"        Ask your doctor if you should take vitamins or work with a nutrition expert",
"       </li>",
"       <li>",
"        If you have side effects from your treatments that are keeping you from eating, these tips might help:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        If you have a dry mouth, drink lots of fluids and avoid foods that are hard or dry (such as toast or crackers). You can eat moist foods, or suck on ice chips or sugar-free hard candy.",
"       </li>",
"       <li>",
"        If you have mouth sores, eat soft foods that you can chew and swallow easily. You can also cut up your food into small pieces or mash it in a blender. Try to avoid spicy or salty foods.",
"       </li>",
"       <li>",
"        If you have nausea, eat foods that are bland and dry, such as crackers, rice, and toast. Avoid foods that are spicy and greasy.",
"       </li>",
"       <li>",
"        If you have trouble having a bowel movement, try to drink more fluids. You can also eat foods with a lot of fiber, such as vegetables, fruits, beans, nuts, oatmeal, and some breads and cereals (",
"        <a class=\"graphic graphic_figure graphicRef79063 \" href=\"UTD.htm?41/38/42598\">",
"         figure 1",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        If you have diarrhea, try to drink a lot of fluids so that your body doesn&rsquo;t lose too much water. Try to avoid milk, greasy foods, and foods with a lot of fiber.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14856222\">",
"      <span class=\"h1\">",
"       When should I call my doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Call your doctor or nurse if you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Are not able to keep any food or drink in your stomach",
"       </li>",
"       <li>",
"        Have severe belly pain",
"       </li>",
"       <li>",
"        Are dizzy or weak",
"       </li>",
"       <li>",
"        Have a fever",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14856229\">",
"      <span class=\"h1\">",
"       Are there medicines that can increase my appetite?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Doctors can prescribe different medicines to help increase a person&rsquo;s appetite. Medicines that doctors commonly use include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Hormone medicines",
"       </li>",
"       <li>",
"        Steroids &mdash; Doctors usually recommend that people not take these medicines for more than a few weeks. Even though these medicines can help, they can also cause problems of their own.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14856236\">",
"      <span class=\"h1\">",
"       Are there other treatments that can help if I have no appetite or lose weight?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Sometimes, doctors use other treatments if people are unable to eat or if their body doesn&rsquo;t take in nutrients from the food they do eat.",
"     </p>",
"     <p>",
"      People who can&rsquo;t eat on their own but whose bodies can digest food might get &ldquo;tube feedings.&rdquo; People who get tube feedings get their food and nutrients through a tube that goes into the stomach or small intestine (",
"      <a class=\"graphic graphic_figure graphicRef55616 \" href=\"UTD.htm?28/22/29024\">",
"       figure 2",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      People whose bodies are unable to digest food might get their nutrition through a thin tube that goes into the vein. But doctors don&rsquo;t usually need to use this type of treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14856243\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/36/579?source=see_link\">",
"       Patient information: Managing pain when you have cancer (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/4/29762?source=see_link\">",
"       Patient information: When your cancer treatment makes you tired (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/57/28562?source=see_link\">",
"       Patient information: Nausea and vomiting in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/5/9299?source=see_link\">",
"       Patient information: Diarrhea in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/51/35634?source=see_link\">",
"       Patient information: High-fiber diet (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=see_link\">",
"       Patient information: What are clinical trials? (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/29/36308?source=see_link\">",
"       Patient information: Acute diarrhea in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?8/39/8817?source=see_link\">",
"       Patient information: High-fiber diet (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?1/40/1667?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16248 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.96.59.103-CEFC7D49B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_40_1667=[""].join("\n");
var outline_f1_40_1667=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14856194\">",
"      What can cause me to lose weight or have no appetite?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14856201\">",
"      Why is it important to eat enough?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14856208\">",
"      What foods can help keep my weight up?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14856215\">",
"      What can I do on my own to eat enough?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14856222\">",
"      When should I call my doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14856229\">",
"      Are there medicines that can increase my appetite?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14856236\">",
"      Are there other treatments that can help if I have no appetite or lose weight?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14856243\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16248\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/38/42598\">",
"      Foods with fiber",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/22/29024\">",
"       Upper digestive tract",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/29/36308?source=related_link\">",
"      Patient information: Acute diarrhea in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/5/9299?source=related_link\">",
"      Patient information: Diarrhea in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/39/8817?source=related_link\">",
"      Patient information: High-fiber diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/51/35634?source=related_link\">",
"      Patient information: High-fiber diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/36/579?source=related_link\">",
"      Patient information: Managing pain when you have cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/57/28562?source=related_link\">",
"      Patient information: Nausea and vomiting in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=related_link\">",
"      Patient information: What are clinical trials? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/4/29762?source=related_link\">",
"      Patient information: When your cancer treatment makes you tired (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_40_1668="Divert bleed endoclip endos";
var content_f1_40_1668=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diverticular bleeding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Closure of a diverticular bleed with two Resolution endoclips. Active bleeding was found initially in a hepatic flexure diverticulum in a patient presenting with severe hematochezia. The upper left image shows the bleeding diverticulum following injection with dilute epinephrine (1:20,000). Clockwise image show deployment of the two clips. The area was subsequently tattooed with India ink. There was no rebleeding with six months of follow-up.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dennis M. Jensen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_40_1668=[""].join("\n");
var outline_f1_40_1668=null;
var title_f1_40_1669="Direct laryngoscopy curved blade";
var content_f1_40_1669=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65358&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65358&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Direct laryngoscopy using a curved blade",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 422px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Direct laryngoscopy using a curved blade. The blade is inserted under direct vision until the tip is positioned in the vallecula. Pulling upward on the laryngoscope handle at 45-degree angle retracts the tongue and at the same time elevates the epiglottis, revealing the vocal cords and glottis. Selection of the appropriate laryngoscope blade is especially important with this technique. A blade that is too small will impinge on the midportion of the tongue, potentially obscuring the landmarks, whereas a blade that is too large can displace the epiglottis posteriorly over the glottic opening.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: King C, Rappaport LD. Emergent endotracheal intubation. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_40_1669=[""].join("\n");
var outline_f1_40_1669=null;
var title_f1_40_1670="Treatment and prevention of cryptosporidiosis";
var content_f1_40_1670=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prevention of cryptosporidiosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/40/1670/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/40/1670/contributors\">",
"     Karin Leder, MBBS, FRACP, PhD, MPH, DTMH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/40/1670/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/40/1670/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/40/1670/contributors\">",
"     Edward T Ryan, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/40/1670/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/40/1670/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/40/1670/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H13466474\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptosporidium is an intracellular protozoan parasite that is associated with self-limited diarrhea in immunocompetent hosts and severe debilitating diarrhea with weight loss and malabsorption in HIV-infected patients.",
"   </p>",
"   <p>",
"    This topic will address the treatment and prevention of cryptosporidiosis in immunocompetent and HIV-infected patients. The epidemiology, pathogenesis, clinical manifestations and diagnosis of cryptosporidiosis are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13961?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of cryptosporidiosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13465782\">",
"    <span class=\"h1\">",
"     TREATMENT OF IMMUNOCOMPETENT PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recovery from Cryptosporidium infection depends largely upon the immune status of the host. Immunologically healthy patients usually have a spontaneous recovery within a few weeks and parasitologic cure within a few months without requiring any specific therapy.",
"   </p>",
"   <p>",
"    When therapy is required,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=see_link\">",
"     nitazoxanide",
"    </a>",
"    , a nitrothiazole benzamide, is the preferred drug in children 1 to 11 years of age and has also been studied in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1670/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multicenter, randomized, double-blind, placebo-controlled trial was conducted in 90 outpatients 12 years of age and older from Egypt [",
"      <a class=\"abstract\" href=\"UTD.htm?1/40/1670/abstract/6\">",
"       6",
"      </a>",
"      ]. Patients were randomly assigned to receive 500 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=see_link\">",
"       nitazoxanide",
"      </a>",
"      (tablet or suspension) or placebo, given twice daily for three days. Clinical improvement at four days posttreatment was significantly greater in patients receiving nitazoxanide (96 versus 41 percent). Furthermore, 93 percent on nitazoxanide were free of cryptosporidium oocysts in each of two posttreatment stool samples compared with only 37 percent of those who received placebo. Response rates to the tablet formulation and oral suspension of nitazoxanide were equivalent.",
"     </li>",
"     <li>",
"      In a randomized trial of 100 adults and children with limited follow-up of 7 to 10 days,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=see_link\">",
"       nitazoxanide",
"      </a>",
"      was associated with significant increases in the resolution of diarrhea within three to four days (88 versus 38 percent with placebo) and in elimination of oocyst shedding (75 versus 20 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/40/1670/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13465789\">",
"    <span class=\"h1\">",
"     TREATMENT IN HIV-INFECTED PATIENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13465797\">",
"    <span class=\"h2\">",
"     Antiretroviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For HIV-infected patients, the most important part of therapy is initiating HAART in order to reconstitute immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1670/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. In such patients, clinical resolution may occur, but it is unclear whether organisms are completely eliminated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13465804\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with severe symptoms, antidiarrheal agents and supportive care with enteral or parenteral nutrition can be considered. Repletion of electrolyte losses by either oral or intravenous routes is important in patients who experience significant volume loss associated with severe diarrhea; &gt;10",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    has been reported in patients with \"cholera-like\" diarrhea, which can be life-threatening without aggressive repletion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1670/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13465811\">",
"    <span class=\"h2\">",
"     Antimicrobial agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;If these measures fail, it is reasonable to consider antimicrobial therapy. However, there is limited efficacy of any of the currently available agents. Due to the clinical impact of persistent cryptosporidial infection, the Centers for Disease Control and Prevention suggests a trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=see_link\">",
"     nitazoxanide",
"    </a>",
"    treatment based on the data below [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1670/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13465818\">",
"    <span class=\"h3\">",
"     Nitazoxanide",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large compassionate use clinical trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=see_link\">",
"     nitazoxanide",
"    </a>",
"    (500 to 1500 mg twice daily) given to 365 HIV-infected individuals with cryptosporidiosis showed that 209 (59 percent) achieved a sustained clinical response while on treatment. Duration of treatment ranged from 1 to 1528 days (median 62 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1670/abstract/10\">",
"     10",
"    </a>",
"    ]. No safety issues were identified even on those on high doses for long durations.",
"   </p>",
"   <p>",
"    Two small randomized trials that evaluated the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=see_link\">",
"     nitazoxanide",
"    </a>",
"    in HIV-infected patients produced conflicting results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a double-blind placebo-controlled crossover study, 66 patients with CD4 counts greater than 50",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      were randomly assigned to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=see_link\">",
"       nitazoxanide",
"      </a>",
"      at 500 mg twice daily or 1000 mg twice daily or placebo for 14 days [",
"      <a class=\"abstract\" href=\"UTD.htm?1/40/1670/abstract/11\">",
"       11",
"      </a>",
"      ]. Both doses produced cure rates superior to the placebo group (63 and 67 versus 25 percent). In contrast, nitazoxanide therapy had no demonstrable efficacy in patients with CD4 counts less than 50",
"      <span class=\"nowrap\">",
"       cells/microL.",
"      </span>",
"     </li>",
"     <li>",
"      A randomized placebo-controlled trial evaluated 96 children with proven cryptosporidial infection, one-half of whom were infected with HIV [",
"      <a class=\"abstract\" href=\"UTD.htm?1/40/1670/abstract/3\">",
"       3",
"      </a>",
"      ]. Among the 49 HIV-seropositive children who were assigned to three days of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=see_link\">",
"       nitazoxanide",
"      </a>",
"      or placebo, treatment did not appear to be of benefit. In contrast, in the HIV-negative children, nitazoxanide led to significant increases in the rate of resolution of diarrhea (56 versus 23 percent) and elimination of C. parvum from the stool (52 versus 14 percent). There was also a suggestion of reduced mortality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A subsequent meta-analysis (seven trials, 169 immunosuppressed participants) found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=see_link\">",
"     nitazoxanide",
"    </a>",
"    did not have any impact on duration and frequency of diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1670/abstract/1\">",
"     1",
"    </a>",
"    ]. Nitazoxanide led to significant evidence of oocyst clearance among HIV-negative participants (RR 0.26; 95% CI 0.09, 0.80) but not among HIV-positive participants (RR 0.71; 95% CI 0.36, 1.37).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13465825\">",
"    <span class=\"h3\">",
"     Paromomycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16099?source=see_link\">",
"     Paromomycin",
"    </a>",
"    is a nonabsorbable aminoglycoside indicated for the treatment of intestinal amebiasis but is not specifically approved for cryptosporidiosis.",
"   </p>",
"   <p>",
"    In a double-blind placebo-controlled trial in HIV-infected adults with cryptosporidiosis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16099?source=see_link\">",
"     paromomycin",
"    </a>",
"    at a dose of 25 to 35",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily was associated with only temporary decreases in symptoms and oocyst excretion, with subsequent relapses after therapy was stopped [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1670/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition, in the meta-analysis noted above, paromomycin did not have any effect on the duration or frequency of diarrheal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1670/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13465832\">",
"    <span class=\"h3\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination therapies such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16099?source=see_link\">",
"     paromomycin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    have been utilized in HIV-infected patients with modest effect [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1670/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13465839\">",
"    <span class=\"h3\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other therapies that have been tried in HIV-infected patients include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/18/14628?source=see_link\">",
"     spiramycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    , diclazuril and letrazuril,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"     atovaquone",
"    </a>",
"    , octreotide and hyperimmune bovine colostrum (HBC), all of which have been associated with only temporary symptomatic benefits at best, without sustained parasitologic cure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1670/abstract/14-16\">",
"     14-16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13465846\">",
"    <span class=\"h1\">",
"     SUMMARY OF TREATMENT RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for treatment depend upon the host.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13465853\">",
"    <span class=\"h2\">",
"     Immunocompetent hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;For immunocompetent hosts, no treatment is necessary unless symptoms persist. For children,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=see_link\">",
"     nitazoxanide",
"    </a>",
"    therapy is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1670/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13465860\">",
"    <span class=\"h2\">",
"     HIV-infected patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;For HIV-infected patients, HAART should be quickly initiated, since immune restoration with a CD4 count greater than 100",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    is associated with complete resolution of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1670/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with greater than 10 liters of stool a day, careful volume and electrolyte supplementation are necessary along with antidiarrheal agents. Oral rehydration packets are advised; in patients with chronic symptoms and weight loss,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    should also be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18681?source=see_link\">",
"     \"Oral rehydration therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=see_link\">",
"     Nitazoxanide",
"    </a>",
"    has a limited effect on clinical symptoms related to cryptosporidiosis in immunocompromised hosts. If CD4 recovery is slow and diarrheal symptoms are persistent and severe, we suggest nitazoxanide 1000 mg twice daily for two to eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1670/abstract/2\">",
"     2",
"    </a>",
"    ], although nitazoxanide by itself is not likely to be effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13465867\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with cryptosporidiosis and HIV infection, the prognosis without immune restoration generally is poor. More than half the patients develop chronic disease, and approximately 10 percent develop fulminant disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1670/abstract/17\">",
"     17",
"    </a>",
"    ]. In one study, the mean survival of HIV-infected patients coinfected with Cryptosporidium was 25 weeks, and was only five weeks for those with fulminant infection [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1670/abstract/17\">",
"     17",
"    </a>",
"    ]. Because fulminant infection is more common with lower CD4 counts and more severe immunosuppression, it is difficult to assess the relative contribution of Cryptosporidium to mortality. However cryptosporidiosis appears to significantly decrease survival independent of other factors [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1670/abstract/18-20\">",
"     18-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sequelae of cryptosporidiosis in immunocompetent patients has been less well studied. This issue was addressed in a study in which a questionnaire was sent two months after the initial diagnosis to 235 patients and 232 controls [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1670/abstract/21\">",
"     21",
"    </a>",
"    ]. Forty percent of the patients reported recurrence of intestinal symptoms (usually mild to moderate) after resolution of the acute illness with either C. hominis or C. parvum infection. Late development of extraintestinal symptoms, such as joint pain, eye pain, headache, dizzy spells, and fatigue all occurred two to three times as often in patients compared to controls. The late symptoms, particularly eye pain and recurrent headache, appeared to be more common with C. hominis infection. Longer term outcomes were not studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13465874\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Good hygiene, such as handwashing and proper disposal of contaminated material, are the most important ways to prevent infection. Oocysts are resistant to most standard purification techniques, including filtration and chlorination. Spores can be eliminated with freezing, boiling, and by high concentrations of ammonia or formalin [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1670/abstract/15\">",
"     15",
"    </a>",
"    ]. Asymptomatic family or other contacts do not routinely require any specific investigation or therapy, but these individuals should be aware that they may be excreting cysts and therefore should take care with their personal hygiene. People with cryptosporidial diarrhea should be advised to avoid swimming in public pools for two weeks after the diarrhea has resolved [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1670/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Boiling or filtering water may decrease the risk of infection in immunosuppressed patients. However, the impact of low concentrations of oocysts in drinking water on human illness is not adequately understood. As a result, this approach is not universally recommended. It is suggested that immunocompromised patients who are at high risk for severe infection limit their exposure to cryptosporidia by minimizing oral exposure to water from lakes, streams, and public swimming pools [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1670/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prophylaxis for Cryptosporidium is not routinely recommended. However, one report suggested",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    given for MAC prophylaxis or therapy was more than 75 percent protective against the development of cryptosporidiosis. No effect was seen from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    , and the significance of this observation is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1670/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/24/6530?source=see_link\">",
"       \"Patient information: Cryptosporidiosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13466493\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recovery from Cryptosporidium infection depends largely upon the immune status of the host. Immunologically healthy patients usually have a spontaneous recovery within a few weeks and parasitologic cure within a few months without requiring any specific therapy. (See",
"      <a class=\"local\" href=\"#H13465782\">",
"       'Treatment of immunocompetent patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If symptoms persist and treatment is necessary,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=see_link\">",
"       nitazoxanide",
"      </a>",
"      therapy is the preferred agent. (See",
"      <a class=\"local\" href=\"#H13465782\">",
"       'Treatment of immunocompetent patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For HIV-infected patients with cryptosporidiosis, antiretroviral therapy is the mainstay of treatment. Immune reconstitution has been associated with resolution of symptoms. While awaiting CD4 cell recovery, supportive measures include antimotility drugs and repletion of electrolyte losses. If these measures do not lead to resolution of symptoms,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=see_link\">",
"       nitazoxanide",
"      </a>",
"      should be initiated with close follow-up for electrolyte abnormalities during severe gastrointestinal symptoms. (See",
"      <a class=\"local\" href=\"#H13465789\">",
"       'Treatment in HIV-infected patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with cryptosporidiosis and HIV infection, the prognosis without immune restoration generally is poor. (See",
"      <a class=\"local\" href=\"#H13465867\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Good handwashing and proper disposal of contaminated material are the most important ways to prevent infection. People with cryptosporidial diarrhea should be advised to avoid swimming in public pools for two weeks after the diarrhea has resolved. Immunocompromised patients should minimize oral exposure to water from lakes, streams, and public swimming pools. (See",
"      <a class=\"local\" href=\"#H13465874\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prophylaxis for Cryptosporidium is not routinely recommended. (See",
"      <a class=\"local\" href=\"#H13465874\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1670/abstract/1\">",
"      Abubakar I, Aliyu SH, Arumugam C, et al. Prevention and treatment of cryptosporidiosis in immunocompromised patients. Cochrane Database Syst Rev 2007; :CD004932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1670/abstract/2\">",
"      Fox LM, Saravolatz LD. Nitazoxanide: a new thiazolide antiparasitic agent. Clin Infect Dis 2005; 40:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1670/abstract/3\">",
"      Amadi B, Mwiya M, Musuku J, et al. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet 2002; 360:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1670/abstract/4\">",
"      Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of Nitazoxanide. J Infect Dis 2001; 184:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1670/abstract/5\">",
"      Smith HV, Corcoran GD. New drugs and treatment for cryptosporidiosis. Curr Opin Infect Dis 2004; 17:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1670/abstract/6\">",
"      Rossignol JF, Kabil SM, el-Gohary Y, Younis AM. Effect of nitazoxanide in diarrhea and enteritis caused by Cryptosporidium species. Clin Gastroenterol Hepatol 2006; 4:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1670/abstract/7\">",
"      Benson CA, Kaplan JE, Masur H, et al. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Recomm Rep 2004; 53:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1670/abstract/8\">",
"      Carr A, Marriott D, Field A, et al. Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet 1998; 351:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1670/abstract/9\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1670/abstract/10\">",
"      Rossignol JF. Nitazoxanide in the treatment of acquired immune deficiency syndrome-related cryptosporidiosis: results of the United States compassionate use program in 365 patients. Aliment Pharmacol Ther 2006; 24:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1670/abstract/11\">",
"      Rossignol JF, Hidalgo H, Feregrino M, et al. A double-'blind' placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico. Trans R Soc Trop Med Hyg 1998; 92:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1670/abstract/12\">",
"      White AC Jr, Chappell CL, Hayat CS, et al. Paromomycin for cryptosporidiosis in AIDS: a prospective, double-blind trial. J Infect Dis 1994; 170:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1670/abstract/13\">",
"      Smith NH, Cron S, Valdez LM, et al. Combination drug therapy for cryptosporidiosis in AIDS. J Infect Dis 1998; 178:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1670/abstract/14\">",
"      Blanshard C, Shanson DC, Gazzard BG. Pilot studies of azithromycin, letrazuril and paromomycin in the treatment of cryptosporidiosis. Int J STD AIDS 1997; 8:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1670/abstract/15\">",
"      Hoepelman AI. Current therapeutic approaches to cryptosporidiosis in immunocompromised patients. J Antimicrob Chemother 1996; 37:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1670/abstract/16\">",
"      Griffiths JK. Treatment for AIDS-associated cryptosporidiosis. J Infect Dis 1998; 178:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1670/abstract/17\">",
"      Blanshard C, Jackson AM, Shanson DC, et al. Cryptosporidiosis in HIV-seropositive patients. Q J Med 1992; 85:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1670/abstract/18\">",
"      Manabe YC, Clark DP, Moore RD, et al. Cryptosporidiosis in patients with AIDS: correlates of disease and survival. Clin Infect Dis 1998; 27:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1670/abstract/19\">",
"      McGowan I, Hawkins AS, Weller IV. The natural history of cryptosporidial diarrhoea in HIV-infected patients. AIDS 1993; 7:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1670/abstract/20\">",
"      Connolly GM, Dryden MS, Shanson DC, Gazzard BG. Cryptosporidial diarrhoea in AIDS and its treatment. Gut 1988; 29:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1670/abstract/21\">",
"      Hunter PR, Hughes S, Woodhouse S, et al. Health sequelae of human cryptosporidiosis in immunocompetent patients. Clin Infect Dis 2004; 39:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1670/abstract/22\">",
"      Davies AP, Chalmers RM. Cryptosporidiosis. BMJ 2009; 339:b4168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1670/abstract/23\">",
"      Goodgame RW. Understanding intestinal spore-forming protozoa: cryptosporidia, microsporidia, isospora, and cyclospora. Ann Intern Med 1996; 124:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1670/abstract/24\">",
"      Holmberg SD, Moorman AC, Von Bargen JC, et al. Possible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV disease. HIV Outpatient Study (HOPS) Investigators. JAMA 1998; 279:384.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16217 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-B007036579-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_40_1670=[""].join("\n");
var outline_f1_40_1670=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13466493\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13466474\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13465782\">",
"      TREATMENT OF IMMUNOCOMPETENT PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13465789\">",
"      TREATMENT IN HIV-INFECTED PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13465797\">",
"      Antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13465804\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13465811\">",
"      Antimicrobial agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13465818\">",
"      - Nitazoxanide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13465825\">",
"      - Paromomycin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13465832\">",
"      - Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13465839\">",
"      - Other therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13465846\">",
"      SUMMARY OF TREATMENT RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13465853\">",
"      Immunocompetent hosts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13465860\">",
"      HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13465867\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13465874\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13466493\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13961?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of cryptosporidiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18681?source=related_link\">",
"      Oral rehydration therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/24/6530?source=related_link\">",
"      Patient information: Cryptosporidiosis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_40_1671="Anterior-apex paddle position";
var content_f1_40_1671=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F59094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F59094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    Anterior/apex position of electrode paddles with a supine patient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 398px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The anterior/apex position is most practical in the emergency setting and is typically used. The paddle or electrode pad held in the rescuer's left hand is placed to the right of the sternum below the clavicle. The paddle or electrode pad held in the rescuer's right hand is placed in the left midaxillary line, lateral to breast tissue, at the level of the nipple. If paddles are used, they must be applied with considerable, firm and steady pressure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Scarfone RJ, Cho CS. Cardioversion and Defibrillation. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_40_1671=[""].join("\n");
var outline_f1_40_1671=null;
var title_f1_40_1672="Prolonged QT interval tutorial";
var content_f1_40_1672=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77018%7ECARD%2F53891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77018%7ECARD%2F53891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prolonged QT interval",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 341px; height: 101px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The corrected QT interval (QTc) is calculated by dividing the QT interval (0.60 seconds) by the square root of the RR interval (0.84 seconds). In this case, the QTc is 0.65 seconds.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Single lead electrocardiogram (ECG) showing torsades de pointes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 141px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is an atypical, rapid, and bizarre form of ventricular tachycardia that is characterized by a continuously changing axis of polymorphic QRS morphologies.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_40_1672=[""].join("\n");
var outline_f1_40_1672=null;
var title_f1_40_1673="Drug-induced thrombocytopenia";
var content_f1_40_1673=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Drug-induced thrombocytopenia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/40/1673/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/40/1673/contributors\">",
"     James N George, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/40/1673/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/40/1673/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/40/1673/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/40/1673/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/40/1673/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician is frequently faced with the problem of a patient presenting with a low platelet count (thrombocytopenia) of uncertain cause. One important and reversible cause is drug-induced immune thrombocytopenia (DITP).",
"   </p>",
"   <p>",
"    In most cases, thrombocytopenia is the only hematologic manifestation of drug toxicity. However, there are exceptions to this general rule:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      -induced thrombocytopenia (HIT) is associated with a hypercoagulable state and thrombosis rather than bleeding. HIT is discussed in a separate section. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=see_link\">",
"       \"Heparin-induced thrombocytopenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some drug-induced disorders, such as aplastic anemia and thrombotic thrombocytopenic purpura, result in thrombocytopenia along with other cytopenias as well as organ involvement. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/36/586?source=see_link&amp;anchor=H7#H7\">",
"       \"Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis\", section on 'Drugs'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link&amp;anchor=H19#H19\">",
"       \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Etiology'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This discussion will focus on patients with isolated thrombocytopenia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In most patients with isolated thrombocytopenia, the pathogenesis is accelerated platelet destruction by drug-dependent, platelet-reactive antibodies. Therefore, this is the focus of this discussion. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Laboratory testing'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      It is critically important that not only prescription drugs be considered as potential etiologies, but also over-the-counter medications, herbal remedies,",
"      <span class=\"nowrap\">",
"       complementary/alternative",
"      </span>",
"      medicines, nutritional supplements, foods, and beverages [",
"      <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'History of drug ingestion'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pathogenesis and clinical management of patients with suspected DITP will be reviewed here [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/2\">",
"     2",
"    </a>",
"    ]. The diagnostic approach to the patient with thrombocytopenia is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=see_link\">",
"     \"Approach to the adult patient with thrombocytopenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19385?source=see_link\">",
"     \"Evaluation and management of thrombocytopenia by primary care physicians\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISMS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3116646\">",
"    <span class=\"h2\">",
"     Accelerated platelet destruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual mechanism of thrombocytopenia caused by drugs is accelerated platelet destruction caused by drug-dependent antibodies. Following the observation that drug-dependent antibodies bind to platelets via their Fab regions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/3\">",
"     3",
"    </a>",
"    ], subsequent studies have documented the various different mechanisms of drug-dependent antibody formation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/2,4\">",
"     2,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reversible drug binding to one of the major platelet surface glycoproteins (GP), most commonly GP",
"      <span class=\"nowrap\">",
"       Ib/V/IX",
"      </span>",
"      or GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa,",
"      </span>",
"      can cause a protein conformational change [",
"      <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/5\">",
"       5",
"      </a>",
"      ]. This structural change results in the exposure of a neoepitope, expressed by a sequence normally concealed within the hydrophobic domains of the membrane protein.",
"     </li>",
"     <li>",
"      The molecular structure of the drug may itself become an integral part of the new antigenic epitope or, alternatively, the drug may increase the affinity of the antibody to the epitope [",
"      <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In both cases, drug association with platelets is by noncovalent binding and the drugs are easily dissociated from platelets by in vitro washing procedures. Thus, demonstration of drug-dependent antibodies requires the continual presence of the suspected drug during the reaction. The reversibility of binding of most drugs to platelets is distinct from the covalent binding of a few drugs (eg, penicillin) to the red cell membrane, which can then stimulate antibody formation via a hapten mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/2,7\">",
"     2,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3116653\">",
"    <span class=\"h2\">",
"     Decreased platelet production",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is evidence that decreased platelet production by megakaryocytes may also contribute to drug-induced thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/8\">",
"     8",
"    </a>",
"    ]. In a study using highly purified megakaryocytes, sera and IgG from several patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    -induced thrombocytopenia resulted in induction of apoptosis, a significant decrease in cell viability, and a marked decrease in proplatelet production [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Antibody specificity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Different drugs may provoke drug-dependent antibodies that preferentially react with glycoproteins GP",
"    <span class=\"nowrap\">",
"     Ib/V/IX,",
"    </span>",
"    GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa,",
"    </span>",
"    GP V, platelet-endothelial cell adhesion molecule-1 (PECAM-1), or perhaps other platelet surface glycoproteins. The most abundant platelet surface glycoproteins, GP",
"    <span class=\"nowrap\">",
"     Ib/V/IX",
"    </span>",
"    and GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa,",
"    </span>",
"    also contain the epitopes for most of the platelet alloantigens. These glycoproteins also are the most common antigen sites for drug-dependent antibodies.",
"   </p>",
"   <p>",
"    In some patients, drug-dependent antibodies may react with multiple different glycoproteins or multiple different epitopes of a single glycoprotein. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of sera from 15 patients with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      -induced thrombocytopenia found that, in the presence of quinine, the antibodies bound to two distinct domains on GP",
"      <span class=\"nowrap\">",
"       Ib/V/IX:",
"      </span>",
"      one on GP Ib-alpha, and one on GP IX [",
"      <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/5\">",
"       5",
"      </a>",
"      ]. Some patients had only one of the antibodies; some had both. In this study, the binding site of one of these antibodies was localized to a region of only 11 amino acids on GP Ib-alpha; however, only 2 of 15 patients had antibodies that reacted only with this epitope. Six had antibodies that reacted with both GP IX and the epitope on GP Ib-alpha, while seven patients had antibodies that reacted with GP IX alone. The specific sequence of the epitope on GP IX remains undefined.",
"     </li>",
"     <li>",
"      Similar data have been obtained with drug-dependent antiplatelet antibodies isolated from patients who developed acute severe thrombocytopenia following the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42888?source=see_link\">",
"       ranitidine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/10\">",
"       10",
"      </a>",
"      ] or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. These antibodies recognized GP IX at apparently the same site or in close proximity to the site involved in the reaction with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      - and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      -dependent antiplatelet antibodies.",
"     </li>",
"     <li>",
"      Drug-dependent antibodies may also recognize antigen sites on platelet-endothelial cell adhesion molecule-1 (PECAM-1, CD31) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/13\">",
"       13",
"      </a>",
"      ]. This was illustrated in a study in which sera from patients with acute mild thrombocytopenia following treatment with carbimazole were analyzed [",
"      <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/14\">",
"       14",
"      </a>",
"      ]. Immunoprecipitation and flow cytometry demonstrated binding of drug-dependent antibodies in the presence of carbimazole to both isoforms of PECAM-1, but not to GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      or GP Ib-IX. Thrombocytopenia in these patients is only moderate, likely because this drug forms a complex with a less abundant platelet glycoprotein [",
"      <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sera from seven patients with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      -dependent antibodies and a history of quinidine-induced thrombocytopenia also reacted with PECAM-1 but, in contrast to carbimazole-dependent antibodies, all seven sera also reacted with GP Ib-IX and three showed reactivity with GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 15 patients who developed thrombocytopenia while taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      or sulfisoxazole, drug-dependent antibodies from all but one of these patients reacted only with the intact GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      molecule, and not with its dissociated components [",
"      <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This latter study also documented the exquisite specificity for the drug. None of the 12 sulfamethoxazole-induced drug-dependent antibodies crossreacted with sulfisoxazole and only one of three sulfisoxazole-induced antibodies crossreacted with sulfamethoxazole in spite of their nearly identical molecular structures. Thus, the neoantigens induced by drugs must be sensitive to minor changes in drug structure. This has been previously demonstrated by the failure of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    - and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    -dependent antibodies to crossreact with the other drug, even though one drug is the optical isomer of the other [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Reactivity with drug metabolites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-dependent antibodies may have specificity for major metabolites as well as the intact drug. In the study of sulfamethoxazole-induced thrombocytopenia, all of 10 antibodies tested against the N1-acetyl metabolite of sulfamethoxazole reacted strongly with this structure in addition to reacting with intact sulfamethoxazole [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/16\">",
"     16",
"    </a>",
"    ]. Similar results have been obtained with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/18\">",
"     18",
"    </a>",
"    ]. Some patients may form drug-dependent antibodies against only the metabolite of a drug, causing negative results when patient sera are tested using the intact parent drug [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/16\">",
"     16",
"    </a>",
"    ]. Other examples are the very common drugs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    , for which drug-dependent, platelet-reactive antibodies have only been identified for drug metabolites and not for the intact drug [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/18\">",
"     18",
"    </a>",
"    ]. A mouse model for detecting drug-dependent antibodies that react with human platelets has been developed to document and identify the role of drug metabolites in the pathogenesis of DITP [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The above-noted studies emphasize that antibodies causing drug-induced thrombocytopenia (DITP) may be formed against a restricted set of epitopes. The drugs implicated in DITP bind only weakly and reversibly to their platelet surface receptors. However, in patients in whom thrombocytopenia occurs, a mechanism must exist for allowing high affinity interactions between antibody, drug, and the platelet surface. The clinical importance of mapping molecular details of the epitopes on the platelet surface glycoproteins is that genetic polymorphisms may be revealed that predispose certain individuals to the development of drug-induced thrombocytopenia. In addition, the critical amino acid sequences for drug-dependent antibody binding to platelets may suggest the identity of homologous regions on other cell surface glycoproteins that may act as antigenic epitopes, contributing to our understanding of the pathogenesis of immune drug-induced damage to other tissues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Special cases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three classes of agents which can cause DITP require special discussion, namely the heparins, the glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors, and gold salts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    can cause an immune-based thrombocytopenia, associated with platelet activation and thrombosis, rather than bleeding. This disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=see_link\">",
"     \"Heparin-induced thrombocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Glycoprotein IIb/IIIa inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of glycoprotein (GP)",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors can be associated with one of two different causes for a low platelet count:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An immune-based thrombocytopenia, with onset often within minutes to hours of administration, rather than within weeks as commonly seen in other drug-induced thrombocytopenias.",
"     </li>",
"     <li>",
"      Pseudothrombocytopenia, a laboratory artifact of no clinical importance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/21/24918?source=see_link\">",
"     \"Thrombocytopenia induced by glycoprotein IIb/IIIa inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Gold salts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gold salts are no longer commonly used for the treatment of rheumatoid arthritis. When they were more commonly used, it was noted that they could be associated with prolonged thrombocytopenia. Gold-induced thrombocytopenia has a propensity to develop long after therapy has been discontinued, to occur more often in patients with HLA-DR3 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/20,21\">",
"     20,21",
"    </a>",
"    ], and to be associated with drug-independent antibodies to platelet glycoprotein V [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/22\">",
"     22",
"    </a>",
"    ]. These findings suggest that the development of thrombocytopenia represents a drug-induced autoimmune phenomenon that should be treated similarly to idiopathic thrombocytopenic purpura (eg, glucocorticoids, intravenous immune globulin, splenectomy) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/21,23\">",
"     21,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19525?source=see_link&amp;anchor=H5#H5\">",
"     \"Major side effects of gold\", section on 'Hematologic disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=see_link\">",
"     \"Treatment and prognosis of immune thrombocytopenia (ITP) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INITIAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical clinical presentation of DITP is the discovery of isolated thrombocytopenia, often severe (ie,",
"    <span class=\"nowrap\">",
"     &lt;20,000/microL",
"    </span>",
"    with clinical bleeding) in a patient taking one or several different medications. In this situation, the critical diagnostic issue is to distinguish between DITP and idiopathic thrombocytopenic purpura (ITP) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=see_link&amp;anchor=H24#H24\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults\", section on 'Drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many patients with DITP have been initially diagnosed as having ITP until a drug-induced etiology was established. The frequency with which this occurs was demonstrated in a case series of 343 consecutive patients with ITP in which 28 (8 percent) were subsequently shown to have DITP [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/25\">",
"     25",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     Quinine",
"    </a>",
"    was the most common etiology (13 of the 28 patients) consistent with other observations that the use of quinine is often overlooked in the initial evaluation of patients with presumed ITP. Three of these patients had a splenectomy for presumed ITP before the drug-induced etiology was discovered. Misdiagnosis of DITP as ITP, with resulting inappropriate treatment, has been repeatedly documented [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     History of drug ingestion",
"    </span>",
"    &nbsp;&mdash;&nbsp;A detailed history, including all of the medications being taken by the patient, is essential. This must include all prescribed drugs, over-the-counter medications such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , herbal preparations, folk remedies, and recent vaccinations. As an example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    is available in a number of preparations, most of which can be obtained over-the-counter as herbal preparations as well as in beverages (eg, tonic water, Schweppes Bitter Lemon) (",
"    <a class=\"graphic graphic_table graphicRef60296 \" href=\"UTD.htm?21/20/21836\">",
"     table 1",
"    </a>",
"    ). All contain enough of the drug to cause thrombocytopenia with a single serving. Explicit questioning is essential because patients commonly assume that when doctors ask about medications, they are only asking about prescribed medications that are taken regularly [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Drugs taken daily that have been initiated within the previous two or three weeks, or drugs (or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      -containing beverages) that are taken intermittently over many months to years are the ones most likely to be associated with DITP.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Episodes of",
"      <strong>",
"       recurrent",
"      </strong>",
"      , acute thrombocytopenia typically have a",
"      <span class=\"nowrap\">",
"       drug/food/beverage,",
"      </span>",
"      herbal preparation etiology [",
"      <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some drugs may cause thrombocytopenia at the time of",
"      <strong>",
"       initial",
"      </strong>",
"      exposure. This commonly occurs with the glycoprotein",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitors, but it has also occurred with other drugs, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/29\">",
"       29",
"      </a>",
"      ] and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/13/35030?source=see_link\">",
"       piperacillin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of DITP can be supported only by resolution of thrombocytopenia after discontinuation of therapy with the suspected drug. However, reviews of drug-induced thrombocytopenia often include extensive lists of so many commonly used drugs that they do not help clinicians decide which agent is the most likely one causing thrombocytopenia. As an example, it is common for patients undergoing percutaneous coronary intervention to receive combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , and a glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    receptor inhibitor; all four are known causes of drug-induced thrombocytopenia. Determining the culprit agent(s) when such a patient develops isolated thrombocytopenia can be a difficult task [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Evidence for particular drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regularly updated systematic reviews have evaluated all published case reports of DITP in an attempt to assess the quality of evidence for particular drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/32\">",
"     32",
"    </a>",
"    ], most recently on October 20, 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/33\">",
"     33",
"    </a>",
"    ]. Standardized criteria were developed to objectively assess the strength of evidence for a causal relationship between the drug and thrombocytopenia (",
"    <a class=\"graphic graphic_table graphicRef76822 \" href=\"UTD.htm?27/11/27835\">",
"     table 2",
"    </a>",
"    ). In addition to documenting the strength of clinical evidence for individual drugs, an important goal of the database was to develop standardized criteria for future case reports and to stimulate publication of reports of thrombocytopenia caused by drugs not yet documented by level I or level II evidence. The literature search for the original review retrieved 581 articles published before December 31, 1997 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/32\">",
"     32",
"    </a>",
"    ]. It has since been supplemented by systematic searches of articles published up to October 20, 2010 (",
"    <a class=\"graphic graphic_table graphicRef76822 \" href=\"UTD.htm?27/11/27835\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/33\">",
"     33",
"    </a>",
"    ]. This large database is available on the author's website &lt;",
"    <a class=\"external\" href=\"file://www.ouhsc.edu/platelets\">",
"     www.ouhsc.edu/platelets",
"    </a>",
"    &gt; and is updated regularly [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most frequently reported drugs associated with thrombocytopenia include [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/2,18,29,35-40\">",
"     2,18,29,35-40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"       Abciximab",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/24/32135?source=see_link\">",
"       Eptifibatide",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/2/13351?source=see_link\">",
"       Tirofiban",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       Quinine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"     </li>",
"     <li>",
"      Other sulfonamides",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"       Linezolid",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       Rifampin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/13/35030?source=see_link\">",
"       Piperacillin",
"      </a>",
"     </li>",
"     <li>",
"      Gold compounds",
"     </li>",
"     <li>",
"      Beta-lactam antibiotics",
"     </li>",
"     <li>",
"      Valproic acid",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/0/14343?source=see_link\">",
"       Measles-mumps-rubella vaccine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       Carbamazepine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       Phenytoin",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory assays are capable of demonstrating the presence of drug-dependent antiplatelet antibodies. These assays are not generally available in routine hospital laboratories and therefore are not helpful for making the diagnosis of DITP at the time of initial presentation. Flow cytometry-based assays to identify drug-dependent platelet antibodies are the most commonly used methods (",
"    <a class=\"graphic graphic_figure graphicRef65492 \" href=\"UTD.htm?16/8/16514\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/2,16,29,41-43\">",
"     2,16,29,41-43",
"    </a>",
"    ]. An animal model using the",
"    <span class=\"nowrap\">",
"     NOD/scid",
"    </span>",
"    mouse may be valuable for identifying metabolite-specific antibodies capable of causing immune thrombocytopenia or hemolytic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Documentation of drug-dependent antiplatelet antibodies is important to confirm the diagnosis of DITP and to reinforce the rule that the patient should never again be exposed to this agent.",
"     </li>",
"     <li>",
"      However, negative in vitro testing results may be obtained from patients with a clinical course suggestive of DITP, even when several different assays are employed [",
"      <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/10,16,44,45\">",
"       10,16,44,45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Reasons for the discrepancies with any of these antibody tests are multiple:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For some methods, there is no clear definition to distinguish a positive from a negative result. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=see_link&amp;anchor=H21#H21\">",
"       \"Heparin-induced thrombocytopenia\", section on 'Defining test positivity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Laboratory assays require a source of the suspected drug. Often the oral or intravenous preparation may have potentially interfering chemicals or may be poorly soluble in the analytical solution.",
"     </li>",
"     <li>",
"      The drug-dependent antibody may react only with a metabolite of the implicated drug (",
"      <a class=\"graphic graphic_figure graphicRef65492 \" href=\"UTD.htm?16/8/16514\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/41,42\">",
"       41,42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Furthermore, no test for drug-dependent antibodies has been validated by continuing the suspected drug when the test result is reported to be negative. As a result, the physician must often use clinical judgment to decide whether to discontinue therapy with one or more of the patient's medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16978898\">",
"    <span class=\"h3\">",
"     Multiple approaches for identifying drugs causing DITP",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, no single approach is able to document that a particular agent is capable of causing DITP. For this reason, three different methods for identifying such drugs were analyzed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/18\">",
"     18",
"    </a>",
"    ]. These included: (1) published case reports (87 identified); (2) presence of drug-dependent platelet-reactive antibodies (67 identified); and (3) a search of the FDA&rsquo;s Adverse Event Reporting System database (573 identified). Among a total of 1468 suspected drugs, 612 were identified by one or more of these methods and 102 were evaluated by all three methods. Of these, 23 had evidence for an association with thrombocytopenia by all three methods. These 23 agents (plus one agent identified only by methods (1) and (2) only) are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef73618 \" href=\"UTD.htm?36/3/36924\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While this listing does not claim to contain all of the agents causing DITP, it provides the most complete useful current information for evaluation and management of patients with suspected DITP. A complete list of all 1468 suspected drugs and the results of evaluations by (1) published case reports, (2) presence of drug-dependent platelet-reactive antibodies, and (3) the FDA&rsquo;s Adverse Event Reporting System is available at",
"    <a class=\"external\" href=\"file://www.ouhsc.edu/platelets\">",
"     file://www.ouhsc.edu/platelets",
"    </a>",
"    . The data for presence of drug-dependent platelet-reactive antibodies are updated annually; the data for analysis of published case reports are updated every two years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of a patient with suspected DITP differs between previously asymptomatic patients seen in an outpatient (office) setting and acutely ill hospitalized patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/30\">",
"     30",
"    </a>",
"    ]. DITP and ITP are more likely in the former, while sepsis and DIC are more often considerations in hospitalized patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/30\">",
"     30",
"    </a>",
"    ]. The differential diagnosis of isolated thrombocytopenia includes the following conditions:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Idiopathic thrombocytopenic purpura",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic (immune) thrombocytopenic purpura (ITP) is a diagnosis of exclusion, and can only be convincingly made in the absence of another cause, including a drug-induced etiology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Heparin-induced thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clear relationship between the onset of thrombocytopenia and use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    must be demonstrated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=see_link&amp;anchor=H15#H15\">",
"     \"Heparin-induced thrombocytopenia\", section on 'Diagnostic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other thrombocytopenic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    acquired hematologic disorders associated with thrombocytopenia are suspected when evaluation of the complete blood count and peripheral smear show the presence of abnormal platelet morphology (eg, Bernard-Soulier syndrome), abnormal cellular maturation (eg, myelodysplastic syndrome), pancytopenia (eg, aplastic anemia), or the presence of abnormal circulating white blood cells (eg, the acute and chronic leukemias). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=see_link\">",
"     \"Approach to the adult patient with thrombocytopenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=see_link&amp;anchor=H26#H26\">",
"     \"Congenital and acquired disorders of platelet function\", section on 'Inherited disorders of platelet function'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thrombocytopenia can also be a secondary phenomenon in patients with non-hematologic disorders (eg, infection, vasculitic disorders, pregnancy). Clinical and laboratory findings (eg, fever, leukocytosis, disseminated intravascular coagulation) will help to direct the clinician to the appropriate underlying cause. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=see_link\">",
"     \"Approach to the adult patient with thrombocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Pseudothrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of pseudothrombocytopenia is based upon the finding of thrombocytopenia and platelet clumping on a peripheral smear made from blood in which the offending anticoagulant was used (",
"    <a class=\"graphic graphic_picture graphicRef68949 \" href=\"UTD.htm?26/15/26872\">",
"     picture 1",
"    </a>",
"    ) in combination with a normal platelet count on a non-anticoagulated blood sample (eg, finger stick) put directly into platelet count diluent fluid. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=see_link&amp;anchor=H7#H7\">",
"     \"Approach to the adult patient with thrombocytopenia\", section on 'Pseudothrombocytopenia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with DITP require no specific treatment, as their platelet counts will recover promptly following withdrawal of the offending agent. When only a single agent is strongly implicated by clinical criteria (",
"    <a class=\"graphic graphic_table graphicRef76822 \" href=\"UTD.htm?27/11/27835\">",
"     table 2",
"    </a>",
"    ), the patient should not receive this agent again and should be advised to wear a medical alert bracelet indicating this fact.",
"   </p>",
"   <p>",
"    Drug-dependent, platelet-reactive antibodies can persist for many years, causing acute, severe thrombocytopenia with a repeat exposure as long as 10 years after the previous exposure. As these antibodies are quite specific for the molecular structure of the drug, in many cases the patient can often receive another agent from the same class of drugs without recurrence of thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/2,46\">",
"     2,46",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Antibody specificity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Treatment in addition to drug withdrawal may be required when severe thrombocytopenia (ie, platelet count",
"    <span class=\"nowrap\">",
"     &lt;10,000/microL)",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bleeding is present [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When bleeding is present but not severe, oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      given once daily is an often-employed option, since drug-induced thrombocytopenia cannot initially be distinguished from immune thrombocytopenic purpura (ITP). However, there is no evidence for the efficacy of glucocorticoids in confirmed drug-induced thrombocytopenia.",
"     </li>",
"     <li>",
"      For patients with major bleeding, the appropriate management includes platelet transfusion. The clinical value of intravenous immune globulin in this setting is unclear, but this agent can be employed if bleeding continues despite the use of platelet transfusions [",
"      <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/47\">",
"       47",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=see_link&amp;anchor=H23#H23\">",
"       \"Treatment and prognosis of immune thrombocytopenia (ITP) in adults\", section on 'Life-threatening bleeding and surgery'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author's systematic review, described above, also documented the clinical course and outcome of patients in whom DITP was supported by definite or probable evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Median recovery after discontinuation of the suspected drug occurred in five to seven days, similar to the median recovery rate of eight days reported from the Danish registry [",
"      <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Twenty-three of 266 (9 percent) patients with definite or probable evidence for drug-induced thrombocytopenia had major hemorrhage, including two patients (0.8 percent) who died of bleeding. This mortality rate from bleeding was lower than the value of 3.6 percent reported from the Danish registry [",
"      <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The author's systematic review revealed no pattern of clinical severity related to the type of drug involved. However, other studies suggest that certain drugs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    , and sulfonamides, are more likely to cause more severe thrombocytopenia with hemorrhagic manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Suspecting drug-induced thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-induced thrombocytopenia (DITP) should be suspected in a patient who presents with new onset of thrombocytopenia without an obvious cause other than drug ingestion. A patient with recurrent episodes of acute thrombocytopenia should be suspected of having a drug-induced etiology. A detailed history, including all of the medications being taken by the patient, is essential. This should include all prescribed drugs, over-the-counter medications, herbal preparations, folk remedies,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    -containing beverages, and recent vaccinations [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'History of drug ingestion'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The most common causes of thrombocytopenia other than drug ingestion depend upon the clinical setting in which the patient presents (eg, outpatient, emergency department, inpatient, intensive care unit). This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19385?source=see_link\">",
"     \"Evaluation and management of thrombocytopenia by primary care physicians\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16978817\">",
"    <span class=\"h3\">",
"     General criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three general criteria required for suspecting the presence of DITP [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1673/abstract/48\">",
"     48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The implicated drug should bear a temporal relationship with thrombocytopenia, usually within one week after beginning a drug for the first time, or more quickly when exposed to the agent on an intermittent basis.",
"     </li>",
"     <li>",
"      The platelet count nadir should be less than 20,000 to",
"      <span class=\"nowrap\">",
"       30,000/microL.",
"      </span>",
"     </li>",
"     <li>",
"      There should not be an alternative explanation for the thrombocytopenia that is more highly probable than DITP.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to a full drug history, the appropriate initial approach for suspected DITP requires evaluation of the complete blood count and white blood cell differential, coupled with examination of the peripheral smear. This is especially true in the case of platelet clumping, in which one or more of the commonly used anticoagulants can cause clumping in vitro (",
"    <a class=\"graphic graphic_picture graphicRef68949 \" href=\"UTD.htm?26/15/26872\">",
"     picture 1",
"    </a>",
"    ), leading to falsely low platelet counts (ie, pseudothrombocytopenia).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Confirming the diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The \"gold standard\" confirmation of DITP is observing that thrombocytopenia disappears when a single potentially causative drug is stopped and reappears when that drug is reintroduced (",
"      <a class=\"graphic graphic_table graphicRef76822 \" href=\"UTD.htm?27/11/27835\">",
"       table 2",
"      </a>",
"      ). The latter maneuver is potentially dangerous and not recommended, since the second episode of thrombocytopenia may lead to severe or fatal bleeding. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Evidence for particular drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory tests for diagnosing DITP are not generally available, but documentation of drug-dependent antiplatelet antibodies in a reference laboratory can confirm the diagnosis based on clinical criteria. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Laboratory testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Treatment and prognosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients with DITP require no specific treatment, as their platelet counts will recover promptly following withdrawal of the offending agent, usually within one week or less. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Clinical course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with severe thrombocytopenia (ie, platelet count",
"      <span class=\"nowrap\">",
"       &lt;10,000/microL)",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      severe bleeding, we recommend the supportive use of platelet transfusions (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The efficacy of other agents (eg, intravenous immunoglobulin) in this setting is unclear.",
"     </li>",
"     <li>",
"      In patients with thrombocytopenic bleeding in whom idiopathic (immune) thrombocytopenic purpura cannot be reliably distinguished from drug-induced thrombocytopenia, treatment with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      given once daily may be considered. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22916633\">",
"    <span class=\"h2\">",
"     Reporting",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If a drug has not been previously reported as a cause of thrombocytopenia with definite or probably clinical evidence (",
"      <a class=\"graphic graphic_table graphicRef76822 \" href=\"UTD.htm?27/11/27835\">",
"       table 2",
"      </a>",
"      ) (",
"      <a class=\"external\" href=\"file://www.ouhsc.edu/platelets\">",
"       www.ouhsc.edu/platelets",
"      </a>",
"      ), it is important to document this observation with a published case report.",
"     </li>",
"     <li>",
"      If a drug has not been previously documented as a cause of thrombocytopenia by demonstration of drug-dependent antibodies (",
"      <a class=\"external\" href=\"file://www.ouhsc.edu/platelets\">",
"       www.ouhsc.edu/platelets",
"      </a>",
"      ), testing for drug-dependent antibodies should be included in the published case report.",
"     </li>",
"     <li>",
"      All occurrences of drug-induced thrombocytopenia should be reported on the FDA&rsquo;s MedWatch website (",
"      <a class=\"external\" href=\"file://www.fda.gov/Safety/MedWatch/default.htm\">",
"       file://www.fda.gov/Safety/MedWatch/default.htm",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/1\">",
"      Royer DJ, George JN, Terrell DR. Thrombocytopenia as an adverse effect of complementary and alternative medicines, herbal remedies, nutritional supplements, foods, and beverages. Eur J Haematol 2010; 84:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/2\">",
"      Aster RH, Curtis BR, McFarland JG, Bougie DW. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management. J Thromb Haemost 2009; 7:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/3\">",
"      Christie DJ, Mullen PC, Aster RH. Fab-mediated binding of drug-dependent antibodies to platelets in quinidine- and quinine-induced thrombocytopenia. J Clin Invest 1985; 75:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/4\">",
"      Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med 2007; 357:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/5\">",
"      Burgess JK, Lopez JA, Berndt MC, et al. Quinine-dependent antibodies bind a restricted set of epitopes on the glycoprotein Ib-IX complex: characterization of the epitopes. Blood 1998; 92:2366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/6\">",
"      Bougie DW, Wilker PR, Aster RH. Patients with quinine-induced immune thrombocytopenia have both \"drug-dependent\" and \"drug-specific\" antibodies. Blood 2006; 108:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/7\">",
"      Aster RH. Drug-induced immune thrombocytopenia: an overview of pathogenesis. Semin Hematol 1999; 36:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/8\">",
"      Greinacher A, Fuerll B, Zinke H, et al. Megakaryocyte impairment by eptifibatide-induced antibodies causes prolonged thrombocytopenia. Blood 2009; 114:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/9\">",
"      Perdomo J, Yan F, Ahmadi Z, et al. Quinine-induced thrombocytopenia: drug-dependent GPIb/IX antibodies inhibit megakaryocyte and proplatelet production in vitro. Blood 2011; 117:5975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/10\">",
"      Gentilini G, Curtis BR, Aster RH. An antibody from a patient with ranitidine-induced thrombocytopenia recognizes a site on glycoprotein IX that is a favored target for drug-induced antibodies. Blood 1998; 92:2359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/11\">",
"      Burgess JK, Lopez JA, Gaudry LE, Chong BH. Rifampicin-dependent antibodies bind a similar or identical epitope to glycoprotein IX-specific quinine-dependent antibodies. Blood 2000; 95:1988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/12\">",
"      Pereira J, Hidalgo P, Ocqueteau M, et al. Glycoprotein Ib/IX complex is the target in rifampicin-induced immune thrombocytopenia. Br J Haematol 2000; 110:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/13\">",
"      Newman PJ. Switched at birth: a new family for PECAM-1. J Clin Invest 1999; 103:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/14\">",
"      Kroll H, Sun QH, Santoso S. Platelet endothelial cell adhesion molecule-1 (PECAM-1) is a target glycoprotein in drug-induced thrombocytopenia. Blood 2000; 96:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/15\">",
"      Warkentin TE. Drug-induced immune-mediated thrombocytopenia--from purpura to thrombosis. N Engl J Med 2007; 356:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/16\">",
"      Curtis BR, McFarland JG, Wu GG, et al. Antibodies in sulfonamide-induced immune thrombocytopenia recognize calcium-dependent epitopes on the glycoprotein IIb/IIIa complex. Blood 1994; 84:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/17\">",
"      Christie DJ, Weber RW, Mullen PC, et al. Structural features of the quinidine and quinine molecules necessary for binding of drug-induced antibodies to human platelets. J Lab Clin Med 1984; 104:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/18\">",
"      Reese JA, Li X, Hauben M, et al. Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. Blood 2010; 116:2127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/19\">",
"      Bougie DW, Nayak D, Boylan B, et al. Drug-dependent clearance of human platelets in the NOD/scid mouse by antibodies from patients with drug-induced immune thrombocytopenia. Blood 2010; 116:3033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/20\">",
"      Coblyn JS, Weinblatt M, Holdsworth D, Glass D. Gold-induced thrombocytopenia. A clinical and immunogenetic study of twenty-three patients. Ann Intern Med 1981; 95:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/21\">",
"      Adachi JD, Bensen WG, Kassam Y, et al. Gold induced thrombocytopenia: 12 cases and a review of the literature. Semin Arthritis Rheum 1987; 16:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/22\">",
"      Garner SF, Campbell K, Metcalfe P, et al. Glycoprotein V: the predominant target antigen in gold-induced autoimmune thrombocytopenia. Blood 2002; 100:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/23\">",
"      von dem Borne AE, Pegels JG, van der Stadt RJ, et al. Thrombocytopenia associated with gold therapy: a drug-induced autoimmune disease? Br J Haematol 1986; 63:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/24\">",
"      George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/25\">",
"      Neylon AJ, Saunders PW, Howard MR, et al. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol 2003; 122:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/26\">",
"      Kojouri K, Perdue JJ, Medina PJ, George JN. Occult quinine-induced thrombocytopenia. J Okla State Med Assoc 2000; 93:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/27\">",
"      Reddy JC, Shuman MA, Aster RH. Quinine/quinidine-induced thrombocytopenia: a great imitator. Arch Intern Med 2004; 164:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/28\">",
"      Achterbergh R, Vermeer HJ, Curtis BR, et al. Thrombocytopenia in a nutshell. Lancet 2012; 379:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/29\">",
"      Von Drygalski A, Curtis BR, Bougie DW, et al. Vancomycin-induced immune thrombocytopenia. N Engl J Med 2007; 356:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/30\">",
"      Rousan TA, Aldoss IT, Cowley BD Jr, et al. Recurrent acute thrombocytopenia in the hospitalized patient: sepsis, DIC, HIT, or antibiotic-induced thrombocytopenia. Am J Hematol 2010; 85:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/31\">",
"      H&ouml;chtl T, Pachinger L, Unger G, et al. Antiplatelet drug induced isolated profound thrombocytopenia in interventional cardiology: a review based on individual case reports. J Thromb Thrombolysis 2007; 24:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/32\">",
"      George JN, Raskob GE, Shah SR, et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 1998; 129:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/33\">",
"      Nguyen L, Reese JA, George JN. Drug-induced thrombocytopenia. An updated systematic review, 2010. Drug Saf 2011.",
"     </a>",
"    </li>",
"    <li>",
"     Search on \"Drug-induced thrombocytopenia\". www.ouhsc.edu/platelets (Accessed on March 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/35\">",
"      Pedersen-Bjergaard U, Andersen M, Hansen PB. Drug-induced thrombocytopenia: clinical data on 309 cases and the effect of corticosteroid therapy. Eur J Clin Pharmacol 1997; 52:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/36\">",
"      Pedersen-Bjergaard U, Andersen M, Hansen PB. Drug-specific characteristics of thrombocytopenia caused by non-cytotoxic drugs. Eur J Clin Pharmacol 1998; 54:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/37\">",
"      Kaufman DW, Kelly JP, Johannes CB, et al. Acute thrombocytopenic purpura in relation to the use of drugs. Blood 1993; 82:2714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/38\">",
"      Pedersen-Bjergaard U, Andersen M, Hansen PB. Thrombocytopenia induced by noncytotoxic drugs in Denmark 1968-91. J Intern Med 1996; 239:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/39\">",
"      ten Berg MJ, Huisman A, Souverein PC, et al. Drug-induced thrombocytopenia: a population study. Drug Saf 2006; 29:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/40\">",
"      Patel N, VanDeWall H, Tristani L, et al. A comparative evaluation of adverse platelet outcomes among Veterans' Affairs patients receiving linezolid or vancomycin. J Antimicrob Chemother 2012; 67:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/41\">",
"      Bougie D, Aster R. Immune thrombocytopenia resulting from sensitivity to metabolites of naproxen and acetaminophen. Blood 2001; 97:3846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/42\">",
"      Bougie DW, Benito AI, Sanchez-Abarca LI, et al. Acute thrombocytopenia caused by sensitivity to the glucuronide conjugate of acetaminophen. Blood 2007; 109:3608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/43\">",
"      Scognamiglio F, Corso C, Madeo D, et al. Flow cytometry in the diagnosis of drug-induced thrombocytopenia: two illustrative cases. Am J Hematol 2008; 83:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/44\">",
"      Leach MF, Cooper LK, AuBuchon JP. Detection of drug-dependent, platelet-reactive antibodies by solid-phase red cell adherence assays. Br J Haematol 1997; 97:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/45\">",
"      Nieminen U, Kekom&auml;ki R. Quinidine-induced thrombocytopenic purpura: clinical presentation in relation to drug-dependent and drug-independent platelet antibodies. Br J Haematol 1992; 80:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/46\">",
"      Royer B, Lee K, Gruson B, et al. Methylprednisolone-induced immune thrombocytopenia. Blood 2010; 115:5431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/47\">",
"      Ray JB, Brereton WF, Nullet FR. Intravenous immune globulin for the treatment of presumed quinidine-induced thrombocytopenia. DICP 1990; 24:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1673/abstract/48\">",
"      Warkentin TE, Anderson JA. DITP causation: 3 methods better than 1? Blood 2010; 116:2002.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6674 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-FE77A46CF4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_40_1673=[""].join("\n");
var outline_f1_40_1673=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3116646\">",
"      Accelerated platelet destruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3116653\">",
"      Decreased platelet production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Antibody specificity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Reactivity with drug metabolites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Special cases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Heparin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Glycoprotein IIb/IIIa inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Gold salts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INITIAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      History of drug ingestion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Evidence for particular drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16978898\">",
"      - Multiple approaches for identifying drugs causing DITP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Idiopathic thrombocytopenic purpura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other thrombocytopenic disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Pseudothrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Clinical course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Suspecting drug-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16978817\">",
"      - General criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Confirming the diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22916633\">",
"      Reporting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/6674\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6674|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/8/16514\" title=\"figure 1\">",
"      Thrombopen drug metabolite",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6674|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/15/26872\" title=\"picture 1\">",
"      Platelet clumping in EDTA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6674|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/20/21836\" title=\"table 1\">",
"      Sources of quinine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/11/27835\" title=\"table 2\">",
"      Drug thrombocytopenia criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/3/36924\" title=\"table 3\">",
"      Drugs associated with immune thrombocytopenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/586?source=related_link\">",
"      Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=related_link\">",
"      Approach to the adult patient with thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=related_link\">",
"      Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=related_link\">",
"      Congenital and acquired disorders of platelet function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19385?source=related_link\">",
"      Evaluation and management of thrombocytopenia by primary care physicians",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=related_link\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19525?source=related_link\">",
"      Major side effects of gold",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/21/24918?source=related_link\">",
"      Thrombocytopenia induced by glycoprotein IIb/IIIa inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=related_link\">",
"      Treatment and prognosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_40_1674="Neuropsychiatric side effects associated with interferon-alfa plus ribavirin therapy: Treatment and prevention";
var content_f1_40_1674=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neuropsychiatric side effects associated with interferon-alfa plus ribavirin therapy: Treatment and prevention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/40/1674/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/40/1674/contributors\">",
"     Charles L Raison, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/40/1674/contributors\">",
"     Nezam H Afdhal, MD, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/40/1674/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/40/1674/contributors\">",
"     Jonathan M Silver, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/40/1674/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/40/1674/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/40/1674/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few well designed studies are available to provide definitive guidance on preventing or alleviating the many neuropsychiatric side effects associated with interferon-alfa (IFN-alfa) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    . Fortunately, several placebo-controlled studies confirm clinical experience by demonstrating that side effects can be managed effectively in many patients. Nonetheless, the recommendations that follow are based mainly upon observational studies and experience in treatment of psychiatric syndromes in other settings.",
"   </p>",
"   <p>",
"    The guidelines found on product information sheets (ie, dosage reduction of IFN-alfa as a treatment for depression) are not sufficiently comprehensive to address the clinical issues that arise during treatment. They do not adequately consider the tradeoff between managing depression and the reduction in efficacy of treatment associated with a dose reduction, especially early in the course of therapy. In addition, the effectiveness of dose-reduction in resolving treatment-emergent neuropsychiatric side effects remains to be conclusively determined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41337?source=see_link\">",
"     \"Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We believe that a better strategy is to use all techniques at our disposal (pharmacological and psychosocial) to allow patients to tolerate full doses of",
"    <span class=\"nowrap\">",
"     IFN-alfa/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    for an appropriate period while minimizing negative impact on emotional and physical well-being and daily functioning.",
"   </p>",
"   <p>",
"    This topic review will summarize the treatment and prevention of neuropsychiatric side effects in patients receiving IFN-alfa plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    for HCV infection. Recognition and risk factors are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24551?source=see_link\">",
"     \"Neuropsychiatric side effects associated with interferon-alfa plus ribavirin therapy: Recognition and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PSYCHOSOCIAL CONTEXT OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comprehensive mental health services for patients undergoing treatment with",
"    <span class=\"nowrap\">",
"     IFN-alfa/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    therapy can be helpful but are not widely available [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Thus, much of the responsibility for assessing and treating neuropsychiatric side effects usually falls to the primary clinical team. Before specific pharmacological treatment strategies are discussed, it is important to discuss an even more fundamental issue, which is the importance of the primary treatment environment in the detection and management of neuropsychiatric side effects.",
"   </p>",
"   <p>",
"    Much clinical experience suggests that patients are far more likely to cope with IFN-alfa side effects and stay on therapy when they are in an involved, supportive, and organized treatment environment. Patient education prior to treatment is essential and should include a clear description of likely side effects, and their time course. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?17/4/17478?source=see_link\">",
"     \"Patient information: Hepatitis C (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Behavioral coping strategies should be emphasized. They can provide symptom relief and help patients feel in control of their symptoms. Such strategies include adequate hydration, graded exercise and preparing one's daily schedule to best accommodate the decreased energy that almost always accompanies treatment.",
"   </p>",
"   <p>",
"    Many treatment centers have found that support groups facilitate the dissemination of this type of information and provide key psychosocial support. Family members should be fully educated on likely side effects of treatment. Educating families can help them anticipate and increase their tolerance to behavioral changes in their family member and help them strategize for ways to maximize the patient's psychosocial support network.",
"   </p>",
"   <p>",
"    Other characteristics of an optimal treatment environment include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use of standardized assessments to identify \"at-risk\" patients prior to treatment. Self-report scales useful to assess depressive symptoms include the Quick Inventory of Depressive Symptoms (QIDS), the Beck Depression Inventory (BDI), Center for Epidemiologic Studies Depression Scale (CES-D).",
"     </li>",
"     <li>",
"      Adequate staffing to allow for ongoing close",
"      <span class=\"nowrap\">",
"       psychosocial/symptom",
"      </span>",
"      follow-up of patients during treatment (especially in the first eight weeks of treatment)",
"     </li>",
"     <li>",
"      The clinical expertise to initiate pharmacological interventions in a timely manner by staff with adequate experience in their use",
"     </li>",
"     <li>",
"      A close working relationship with mental health providers who are familiar with issues related to",
"      <span class=\"nowrap\">",
"       IFN-alfa/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"        ribavirin",
"       </a>",
"      </span>",
"      to whom patients can be referred for a rapid evaluation when symptoms escalate beyond the expertise of staff members.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is very likely that specific psychotherapeutic interventions tailored to the unique situation of patients on",
"    <span class=\"nowrap\">",
"     IFN-alfa/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    would augment the more non-specific recommendations given thus far. However, demonstration of efficacy for techniques based on individualized psychotherapies (eg, cognitive-behavioral or interpersonal psychotherapy) awaits results from appropriately designed studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     WHO CAN BE SAFELY TREATED WITH INTERFERON",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HCV who also have significant psychiatric illnesses have been often been excluded from treatment with IFN out of concern for the medication's well documented ability to worsen cognitive and emotional functioning, However, clinicians increasingly recognize the need to treat these patients, and accumulating experience suggests that many patients with pre-existing psychiatric disorders can tolerate IFN and obtain viral clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Even patients with severe mental illnesses, such as schizophrenia, can tolerate and benefit from IFN [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Thus, a psychiatric history per se should not automatically disqualify a patient for IFN therapy.",
"   </p>",
"   <p>",
"    However, given evidence that baseline mood symptoms strongly predict depressive symptoms during therapy, it is of great importance that all patients with a psychiatric history be as stable as possible prior to initiation of IFN. This will typically require close collaboration with a treating psychiatrist. Patients who are severely depressed, suicidal, manic, or grossly psychotic are best treated only when these symptoms have been adequately treated.",
"   </p>",
"   <p>",
"    Data from a large Veteran's Administration population highlight the challenges of optimizing emotional functioning prior to commencing IFN-alfa [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/5\">",
"     5",
"    </a>",
"    ]. Many patients responded poorly to antidepressant treatment, suggesting that patients who require IFN-alfa therapy may enter treatment with psychiatric vulnerabilities despite attempts at antidepressant pretreatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     WHEN TO TREAT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic therapy should be considered before beginning interferon-alfa (IFN-alfa) in patients with risk factors for a mood disturbance. In other patients it can be started after development of its initial features provided that the treatment settings permit close follow-up to detect these early features. We generally suggest beginning antidepressant treatment in such patients if they have had seven or more days of continuous depressive symptoms of mild or greater severity.",
"   </p>",
"   <p>",
"    These suggestions are based on the assumption that patients at greatest risk for treatment-emergent symptoms are also those most likely to benefit from antidepressant pretreatment. This approach was supported by at least one placebo-controlled trial, which found a significant benefit to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    pretreatment in patients with depressive symptoms before treatment, but no benefit in patients who did not have depressive symptoms prior to IFN-alfa therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most physicians who treat depression or anxiety disorders play a constant game of \"catch-up\" with symptoms that are already present and impairing daily life. On the other hand, clinicians are in a unique and potentially fortunate situation when it comes to addressing IFN-alfa-induced neuropsychiatric side effects, because they have the option of pretreating patients before beginning antiviral therapy in hopes of preventing, or at least alleviating, treatment-emergent symptoms.",
"   </p>",
"   <p>",
"    A well-designed double blind, placebo-controlled trial of patients receiving high-dose IFN-alfa monotherapy for malignant melanoma found that pretreatment with the antidepressant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    was associated with a significant reduction in IFN-alfa-induced depression (from 45 to 11 percent) thereby allowing a significantly higher percentage of patients to continue treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/6\">",
"     6",
"    </a>",
"    ]. Open-label trials in patients with hepatitis C virus suggest that antidepressant pretreatment may also help prevent or reduce depression during combined",
"    <span class=\"nowrap\">",
"     IFN-alfa/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    therapy&mdash;especially in patients at risk because of current or past psychiatric symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized trials of antidepressant pretreatment have yielded conflicting results. Two reported limited or no benefit of pretreatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/9,10\">",
"     9,10",
"    </a>",
"    ], whereas three other trials found that pretreatment with either paroxetine [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/4\">",
"     4",
"    </a>",
"    ] or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/56/25481?source=see_link\">",
"     escitalopram",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/11,12\">",
"     11,12",
"    </a>",
"    ] reduced the likelihood that patients would develop moderate or greater depressive symptoms during at least six months of therapy with pegylated interferon-alpha plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    . As an example, a trial compared escitalopram (10 mg per day) with placebo in 181 patients who had no prior psychiatric history and were infected with the hepatitis C virus; study drugs were started 2 weeks prior to administration of IFN-alfa plus ribavirin and continued for at least 24 weeks during antiviral therapy. Onset of major depression occurred in fewer patients who received escitalopram than placebo (8 versus 19 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Also relevant are the side effects and risks of the antidepressants, and the observation that only 20 to 40 percent of patients develop significant depression. Thus, pretreating all patients may expose a significant proportion to an additional medication burden they do not need and from which they will not benefit. Given this, it is encouraging that antidepressants also seem to be effective in reducing depression once it has emerged during",
"    <span class=\"nowrap\">",
"     IFN-alfa/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    therapy&mdash;in most cases allowing affected patients to recover sufficiently to continue their antiviral treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/13-24\">",
"     13-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This approach was supported in a randomized, double-blind, placebo-controlled trial that confirmed the effectiveness of antidepressants in reducing depressive symptoms that emerged during treatment with",
"    <span class=\"nowrap\">",
"     IFN-alfa/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/25\">",
"     25",
"    </a>",
"    ]. Patients randomized to the SRI",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    had a significant reduction in IFN-alfa induced depressive symptoms within four weeks, whereas no effect was observed for placebo. The lack of an appreciable placebo response was observed in a prior study of high dose IFN-alfa for malignant melanoma and may differentiate IFN-alfa induced depression from other forms of major depression in which a substantial placebo response is typically seen [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, available data support the usefulness of antidepressants both as a prophylactic strategy for at-risk individuals and as a treatment for symptoms that emerge once antiviral therapy has started.",
"   </p>",
"   <p>",
"    Symptomatic treatment strategies are most appropriate for patients without pretreatment depressive or anxiety symptoms, and in treatment settings in which routine depression screening is available during IFN-alfa treatment. This latter point is especially important, given the rapidity with which IFN-alfa-induced depressive symptoms often emerge and the typical time lag of four to six weeks for a full therapeutic response to antidepressants. Interestingly, only two weeks of symptoms are required to meet DSM-IV criteria for major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/26\">",
"     26",
"    </a>",
"    ], emphasizing that even in the context of idiopathic depression, symptoms need not be present for an extended period for treatment to be indicated. This is even truer in the context of",
"    <span class=\"nowrap\">",
"     IFN-alfa/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    therapy where the known depressogenic factor will continue to adversely affect the patient, often for months or years of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DEPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accumulating data indicate that antidepressants are effective in reducing depressive symptoms, whether initiated before beginning",
"    <span class=\"nowrap\">",
"     IFN-alfa/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    or after symptoms have emerged on therapy (",
"    <a class=\"graphic graphic_algorithm graphicRef82012 \" href=\"UTD.htm?12/56/13187\">",
"     algorithm 1",
"    </a>",
"    ). Much clinical experience and observational studies suggest that antidepressants also effectively diminish treatment-emergent irritability in many patients, although clinicians should be aware of the risk of mania (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Mania'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/13,16\">",
"     13,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Selective serotonin reuptake inhibitors (SSRIs), especially",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      , have been most extensively studied [",
"      <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/7,13,14,17,25,27-31\">",
"       7,13,14,17,25,27-31",
"      </a>",
"      ]. However, some studies have found no benefit for prophylactic treatment. As an example, a 12-week randomized trial compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/56/25481?source=see_link\">",
"       escitalopram",
"      </a>",
"      15 mg per day with placebo in 129 chronic hepatitis C patients without a psychiatric disorder who were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/27/27064?source=see_link\">",
"       pegylated interferon alfa-2a",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/32\">",
"       32",
"      </a>",
"      ]. The rate of major depression did not differ significantly between patients who received interferon compared with placebo (8 versus 3 percent).",
"     </li>",
"     <li>",
"      Other antidepressants may be effective. Indeed, agents with norepinephrine activity may have more activity against painful symptoms than do SSRIs, and hence might be especially valuable in the context of antiviral therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/33\">",
"       33",
"      </a>",
"      ]. Combined serotonin-norepinephrine reuptake inhibitors (SNRIs) available in the United States include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/33/18967?source=see_link\">",
"       desvenlafaxine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      . However, the Food and Drug Administration has issued a precaution about the use of duloxetine in patients with chronic liver disease and thus it is probably not a good choice [",
"      <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other options include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      , an agent with norepinephrine and dopamine activity, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"       mirtazapine",
"      </a>",
"      , a novel agent with effects on norepinephrine and serotonin. Bupropion may be especially useful for fatigue and has an added benefit in lacking the sexual side effects of serotonergic agents. Mirtazapine promotes sleep and weight gain. Both these agents are also frequently used to augment SRIs in patients who do are not fully responsive to the initial treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Less is known about any potential benefits of older agents such as tricyclic antidepressants or monoamine oxidase inhibitors in patients receiving",
"      <span class=\"nowrap\">",
"       IFN-alfa/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"        ribavirin",
"       </a>",
"       ,",
"      </span>",
"      although because of increased side effects and risk of toxicity, these medications are no longer typically used as first line treatments. Similarly, no data have been published concerning use of the newly available monoamine oxidase transdermal patch.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     FATIGUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatigue is the most common neuropsychiatric side effect associated with IFN-alfa [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/36\">",
"     36",
"    </a>",
"    ]. As a result, it is especially disconcerting that SRIs (the most commonly used antidepressants) are not optimal treatment choices for fatigue. Several lines of evidence suggest that serotonergic treatment strategies are generally not as effective for somatic symptoms as they are for the emotional symptoms of depression [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/36-38\">",
"     36-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of most direct relevance to patients undergoing antiviral therapy, the SRI",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    was significantly more effective than placebo in reducing depressed mood, anxiety and cognitive complaints but not more effective than placebo in reducing fatigue, sleep complaints and appetite loss in patients receiving high dose IFN-alfa monotherapy for malignant melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/36\">",
"     36",
"    </a>",
"    ]. Thus many patients with full-blown IFN-alfa-induced depression may feel better emotionally (ie, less sad, more hopeful, less irritable) following initiation of an SRI but may well be left with inadequately treated fatigue. Conversely, patients who present with IFN-alfa-induced fatigue without other prominent depressive symptoms may derive no benefit at all from SRI treatment, while being subjected to the additional side effect burden (ie, loss of libido, GI complaints, disrupted sleep) associated with these agents.",
"   </p>",
"   <p>",
"    Before considering pharmacologic interventions, the clinician should suggest behavioral strategies that improve fatigue and help patients adjust their activities to its presence. Treatment of fatigue is difficult. Unfortunately, reduction of the dose of IFN or RBV does not reliably improve fatigue. We suggest patients conserve energy by taking frequent rest periods, napping, if possible, and planning physical tasks and household tasks to be spread out over the course of the day. A gradual exercise-tolerance program, involving light exercise such as a daily walk, can be useful if initiated at the beginning of therapy, to condition patients to a higher level of activity and improve physical functioning, to better cope with fatigue.",
"   </p>",
"   <p>",
"    Adequate fluid balance is also critical in dealing with fatigue. IFN can affect the hypothalamic temperature center, resulting in an increase in core body temperature, which leads to low-grade fevers and fatigue. Adequate hydration with caffeine-free fluids can counterbalance this effect and lead to improvement in energy levels. A good rule of thumb is to divide the patient's weight by 2, which equals the daily recommended intake of fluids in fluid ounces (eg, 160 lb woman = 80 fl",
"    <span class=\"nowrap\">",
"     oz/d).",
"    </span>",
"   </p>",
"   <p>",
"    At present, the best documented treatment for fatigue associated with antiviral therapy are growth factors used to maintain adequate hemoglobin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Due to a lack of adequate controlled trials, further recommendations for agents to treat",
"    <span class=\"nowrap\">",
"     IFN-alfa/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"     -induced",
"    </span>",
"    fatigue must be considered provisional, because they are based on data from other disease-states. Having said this, significant data suggest that agents that modulate catecholamine signaling in the central nervous system reliably reduce fatigue and increase wakefulness.",
"   </p>",
"   <p>",
"    Psychostimulants (especially",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    and dextro-amphetamine) reduce fatigue in healthy controls and in patients with a number of medical illnesses [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. Our clinical experience suggests that many patients with",
"    <span class=\"nowrap\">",
"     IFN-alfa/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"     -induced",
"    </span>",
"    fatigue improve significantly with the addition of one of these agents to their regimen (either as an add-on to an antidepressant in patients with a full panoply of depressive symptoms, or as a single agent in fatigued patients without other depressive symptoms). However, psychostimulants are associated with abuse liability, which can make their use problematic in many patients with substance abuse issues.",
"   </p>",
"   <p>",
"    Potential alternatives include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The non-stimulant wake promoter",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"       modafinil",
"      </a>",
"      (Provigil&reg;), which has received significant interest for the treatment of fatigue (although current data are mixed)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"       Ondansetron",
"      </a>",
"      , a serotonin 5-HT3 receptor antagonist improved fatigue in HCV patients (who were not on IFN) in a placebo-controlled trial [",
"      <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/44\">",
"       44",
"      </a>",
"      ]. Its role in treatment-emergent fatigue is unclear, particularly since it can be associated with constipation.",
"     </li>",
"     <li>",
"      The activating antidepressant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"     </li>",
"     <li>",
"      Dopamine agonists (ie,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18615?source=see_link\">",
"       ropinirole",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/19/32055?source=see_link\">",
"       pramipexole",
"      </a>",
"      ), while occasionally causing fatigue, also show promise for the treatment of fatigue in other conditions and might be of potential benefit in subjects receiving",
"      <span class=\"nowrap\">",
"       IFN-alfa/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"        ribavirin",
"       </a>",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/45\">",
"       45",
"      </a>",
"      ]. Consistent with this,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"       amantadine",
"      </a>",
"      , an antiviral agent with dopaminergic properties, was useful in the treatment of",
"      <span class=\"nowrap\">",
"       IFN-alfa/ribavirin-induced",
"      </span>",
"      depressive symptoms when compared to placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INSOMNIA, PAIN, ANOREXIA AND IRRITABILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with fatigue, other single neuropsychiatric symptoms are frequently the tip of a larger iceberg of emotional and physical suffering. Thus many patients who focus their complaints on fatigue, pain, or insomnia will be found, upon closer questioning, to be suffering from a diagnosable depressive condition [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/47\">",
"     47",
"    </a>",
"    ]. In the context of",
"    <span class=\"nowrap\">",
"     IFN-alfa/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    therapy, patients who really do only have one or two somatic symptoms are nonetheless at greatly increased risk for full major depression as the treatment progresses [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/48\">",
"     48",
"    </a>",
"    ]. As a result, it makes clinical sense to fully evaluate and treat all symptomatic complaints to the fullest extent possible, both to improve health-related quality of life during antiviral therapy and also to attempt to prevent a worsening with continued treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Insomnia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal management strategies for insomnia may require both behavioral and pharmacologic options. Thus, insomnia should be addressed through instruction in good sleep hygiene, as well as through factors specific to treatment. For example, consuming large quantities of water may aid with fatigue, but this strategy can become counterproductive if patients drink so much fluid in the evening that they suffer sleep disruption from need to urinate.",
"   </p>",
"   <p>",
"    Many of the available sleeping agents have been used in patients on",
"    <span class=\"nowrap\">",
"     IFN-alfa/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"     ,",
"    </span>",
"    although none have been adequately studied for this indication.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Frequently prescribed agents include the non-benzodiazepine hypnotics",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/48/13064?source=see_link\">",
"       zolpidem",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/24/17798?source=see_link\">",
"       zopiclone",
"      </a>",
"      , which appear to have less addictive potential than the traditional benzodiazepines.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"       Trazodone",
"      </a>",
"      , a sleep promoting antidepressant, is safe, frequently effective across a wide dosage range (ie, 25 to 150 mg) and is especially useful for patients with abuse potential who require long-term treatment. Other agents that do not have primary indications for insomnia but that are widely used to aid sleep include the antidepressant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"       mirtazapine",
"      </a>",
"      (typically at doses between 7.5 mg and 60 mg) and the atypical antipsychotic agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      (typically at doses between 25 and 100 mg).",
"     </li>",
"     <li>",
"      Over the counter sleeping preparations typically contain",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      , an agent with anticholinergic effects that have the potential to add to the side effect burden in some patients on",
"      <span class=\"nowrap\">",
"       IFN-alfa/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"        ribavirin",
"       </a>",
"      </span>",
"      and are thus generally not good choices.",
"     </li>",
"     <li>",
"      Whether the novel melatonin modulating sleep agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15125?source=see_link\">",
"       ramelteon",
"      </a>",
"      will be of benefit during therapy has yet to be determined.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Aches and pains",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bodily aches and pains are common in patients on",
"    <span class=\"nowrap\">",
"     IFN-alfa/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"     .",
"    </span>",
"    While not typically considered \"neuropsychiatric side effects\", pain complaints are nonetheless extremely common in the context of depression and are a risk factor for the development of mood disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/38,47\">",
"     38,47",
"    </a>",
"    ]. Furthermore, certain pain syndromes (especially neuropathic pain) respond to antidepressants with norepinephrine activity, even in patients who are not depressed.",
"   </p>",
"   <p>",
"    The SNRI",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    has been best studied but data also support the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    and older tricyclic antidepressants [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/49-59\">",
"     49-59",
"    </a>",
"    ]. As noted above, the FDA has issued a precaution regarding use of duloxetine in patients with chronic liver disease and thus it is probably not a first-line choice at this time.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     Bupropion",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    may also be effective for pain, although there are limited data [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/60-63\">",
"     60-63",
"    </a>",
"    ]. On a more fundamental level, techniques that help patients manage pain without resorting to addictive medications (ie, opiates) are probably protective against the development of depression during treatment. For example, many patients experience a significant increase in pain and malaise in the day or two following their weekly injection. The judicious use of non-steroidal anti-inflammatory agents to suppress this weekly experience would be expected to decrease emotional and physical changes (ie, cytokine production) that promote the development of depression. The safety of pain medications in patients with advanced liver disease is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10007?source=see_link\">",
"     \"Management of pain in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Anorexia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of nutritional supplements are available as a first-line strategy in helping anorexic patients consume adequate calories. In patients who fail these interventions, the use of weight promoting psychotropic agents can occasionally be helpful. Such agents include the antidepressant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    and the atypical antipsychotic agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    . However, the benefits of this type of strategy need to be weighed against potential dangers, including the association of olanzapine with insulin resistance and the rare development of agranulocytosis patients treated with mirtazapine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Irritability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Widespread clinical experience and observational studies suggest that many, and perhaps most, patients who develop irritability during",
"    <span class=\"nowrap\">",
"     IFN-alfa/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    therapy benefit from the initiation of an antidepressant with serotonergic activity (ie, an SRI or SNRI) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/13,16\">",
"     13,16",
"    </a>",
"    ]. This should not be surprising given a large body of evidence attesting to the value of these agents in patients that are irritable for other reasons (ie, presence of a personality disorder or organic injury). In an open trial, benzodiazepines were also found to be effective for",
"    <span class=\"nowrap\">",
"     IFN-alfa/ribavirin-induced",
"    </span>",
"    irritability [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MANIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients on IFN-alfa occasionally develop frank mania, with diminished sleep, euphoric mood and increased energy, speech production, and risk-taking behavior. How many of these subjects had undiagnosed bipolar disorder prior to therapy is unknown, although mania does appear to occur de novo during treatment. More commonly seen are patients who develop extreme irritability, often with increased aggression, but who also complain of fatigue and lowered mood while on antiviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/64\">",
"     64",
"    </a>",
"    ]. How these presentations should be classified (ie, depression with irritability versus dysphoric mania) is a topic of some debate that would be of less urgency were it not for the very different treatment strategies required by manic versus depressed conditions.",
"   </p>",
"   <p>",
"    Antidepressants do not typically help manic symptoms, and, in fact, have been known for years to be capable of inducing manic episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/65\">",
"     65",
"    </a>",
"    ]. On the other hand, several classes of medications (often lumped together as \"mood stabilizers\") are remarkably effective in curtailing mania. Such agents include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , valproic acid,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    and both typical (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    ), as well as atypical antipsychotic drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    (Risperdal&reg;),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    . Thus, how any given patient on the continuum between mild irritability and frank mania is classified will directly indicate which type of treatment should be instituted.",
"   </p>",
"   <p>",
"    Suggestions for differentiating dysphoric mania from depression are given in Table 1 (",
"    <a class=\"graphic graphic_table graphicRef74302 \" href=\"UTD.htm?28/14/28907\">",
"     table 1",
"    </a>",
"    ). However, it must be emphasized that no clear empiric data are available to guide the clinician who must choose between an antidepressant and a mood stabilizer in any given patient on",
"    <span class=\"nowrap\">",
"     IFN-alfa/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    with irritability. Sometimes family members can prove invaluable in this regard, given that manic patients frequently lack insight into the seriousness of their condition. Whenever an irritable patient's self report diverges significantly from the reports of others, one must worry that a manic phenomenon is underway, especially if the patient's behavior has changed dramatically after starting antiviral therapy.",
"   </p>",
"   <p>",
"    Consensus has not been achieved on how patients who develop mania while on treatment should be treated. Treatment decisions are probably best guided by drawing upon the research and clinical experience of psychiatry more generally. Psychiatrists recognize full-blown manic episodes as clinical emergencies that are usually best handled by admission to an inpatient unit. If this is not possible, it is of utmost importance to provide the safest environment possible for the patient and to institute treatment promptly.",
"   </p>",
"   <p>",
"    Antidepressant medications should be discontinued immediately and sleep should be induced. If a psychiatrist cannot see the patient within 24 hours, the patients should be started on some type of anti-manic therapy while awaiting more definitive psychiatric care. Atypical antipsychotics, while not without risks and side effects, are probably the easiest \"stop-gap\" measure and often produce dramatic results within a relatively short period of time (ie, days rather than weeks). Commonly used atypical antipsychotics include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    or valproic",
"    <span class=\"nowrap\">",
"     acid/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"      carbamazepine",
"     </a>",
"    </span>",
"    require specific blood tests and close therapeutic monitoring early in treatment, and for these reasons, they may not be good choices for those unfamiliar with their use. Benzodiazepines are frequently of great value as adjunctive agents, both to aid in behavioral control and to extend the sleep period. Given the severity of mania, it is also of central importance to carefully weigh the benefits of ongoing antiviral therapy against the very real risks associated with mania. In most cases of mania, IFN is best stopped. Whether it should ever be restarted once the patient has been stabilized is an issue probably best decided on a case by case basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     HOW LONG SHOULD TREATMENT LAST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antidepressants begin to diminish IFN-induced depression and irritability within two weeks of initiation. However, antidepressants can take six weeks or more to have a full effect. Anti-manic agents tend to work more rapidly; therefore the clinician should expect to see improvement in mania within a week of initiating an atypical antipsychotic. When using psychostimulants for fatigue or various agents for insomnia, the clinician should expect to see an effect immediately. If such an effect is not observed, an alternate strategy should be used.",
"   </p>",
"   <p>",
"    If a patient on IFN responds favorably to a pharmacological intervention, the intervention should be continued throughout the course of IFN, and should be maintained afterward for at least a month. Following a course of IFN, we suggest keeping patients on antidepressants at least until they have returned to their baseline level of emotional and behavioral functioning. Because antidepressants are associated with withdrawal syndromes, especially when discontinued abruptly, all antidepressants should be tapered off over a period of weeks when possible. No data exist to guide the clinician on when to discontinue psychostimulants or anti-manic agents following cessation of IFN&mdash;such decisions rely exclusively on clinical judgment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUICIDAL IDEATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with IFN-alfa has been associated with both attempted and completed suicides. The essence of treatment for suicidal ideation is to keep the patient alive long enough for the symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    situations driving the desire to die to be adequately addressed and resolved. When the risk for self-harm is high, safety is usually best maintained by admission to an inpatient psychiatric unit. When this is impossible, patients with suicidal ideation require careful monitoring and the best available oversight by family members or other loved ones.",
"   </p>",
"   <p>",
"    Anxiety and agitation are two of the most important short-term predictors of suicidal attempts and completions in depressed patients. Thus they are especially ominous in patients receiving IFN-alfa who develop suicidal ideation. For this reason they should be aggressively treated if present. Depression, mania, and active substance abuse are all associated with increased suicide risk; however, all patients on",
"    <span class=\"nowrap\">",
"     IFN-alfa/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    should probably be queried for the presence of suicidal ideation as part of their medical evaluation. At the least, suicidal ideation should be carefully evaluated in all patients who present with other symptoms of a mood",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anxiety disturbance. The development of serious suicidal ideation (defined as significant thoughts of killing one's self, with a concrete plan and the means to carry out the plan) should prompt the discontinuation of IFN and an immediate psychiatric referral to evaluate the need for hospitalization.",
"   </p>",
"   <p>",
"    This subject is often best broached by asking an initial question concerning whether life still feels worthwhile. If answered in the negative, the clinician should follow up by directly asking if the patient has had a wish to die. If answered in the affirmative, the clinician should ask whether the patient has considered harming",
"    <span class=\"nowrap\">",
"     him/herself.",
"    </span>",
"    If this is answered in the affirmative, the clinician should ask if the patient has a plan and the means to carry out this plan. If the patient acknowledges this, an immediate intervention should be made, which will usually take the form of assuring that the patient is escorted safely to an emergency room for further evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     IFN-alfa in patients with psychiatric illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with serious preexisting psychiatric illnesses such as schizophrenia, bipolar disorder, severe depression, and recent or current substance abuse pose a special challenge. While often excluded from treatment in the past, with proper management many patients with significant psychopathology can be successfully shepherded through a full course of antiviral therapy, and should therefore not be automatically excluded from treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/40/1674/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, patients should be as psychiatrically stable as possible prior to beginning therapy, and often this may require more aggressive management than is currently in place. It is especially important for mood states to be within the normal range. Given the complexities involved, it is clearly preferable for treating clinicians to co-manage these patients with mental health professionals experienced in the psychiatric risks and benefits of",
"    <span class=\"nowrap\">",
"     IFN-alfa/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"     .",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients are likely to best cope with",
"      <span class=\"nowrap\">",
"       IFN-alfa/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"        ribavirin",
"       </a>",
"      </span>",
"      in the context of an active, caring, and competent treatment environment that provides pretreatment education and assessment and careful monitoring during therapy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Psychosocial context of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that pharmacologic therapy be given before beginning IFN in patients with risk factors for a mood disturbance (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In other patients it can be started after development of its initial features provided that the treatment settings permit close follow-up to detect these early features (",
"      <a class=\"graphic graphic_table graphicRef57222 \" href=\"UTD.htm?17/49/18203\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef82012 \" href=\"UTD.htm?12/56/13187\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24551?source=see_link\">",
"       \"Neuropsychiatric side effects associated with interferon-alfa plus ribavirin therapy: Recognition and risk factors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      All patients with psychiatric disorders should be in active effective treatment before beginning treatment, and all attempts should be made to \"tune-up\" patients as much as possible. This often requires ongoing collaboration with a psychiatrist or other mental health professional who is overseeing a given patient's psychopharmacological regimen (",
"      <a class=\"graphic graphic_algorithm graphicRef82012 \" href=\"UTD.htm?12/56/13187\">",
"       algorithm 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Single symptoms of fatigue, sleep disturbance, pain or irritability predict the later development of full major depression. As a result, patients presenting with any of these symptoms should be evaluated carefully for the presence of a full depressive syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24551?source=see_link\">",
"       \"Neuropsychiatric side effects associated with interferon-alfa plus ribavirin therapy: Recognition and risk factors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients considered to have (or be at risk for) depression, we suggest pharmacologic intervention using the approached discussed above (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Depression'",
"      </a>",
"      above.) SRIs have been best studied but other options may be equally effective and possibly preferable in patients in whom certain characteristics predominate but who do appear to have depression. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Insomnia, pain, anorexia and irritability'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SRIs may be of limited us in patients with fatigue, but without other significant depressive symptoms. Patients should be counseled on the behavioral modifications described above. In those who do not respond, we suggest treatment with psychostimulants such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"       modafinil",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The antidepressant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"       mirtazapine",
"      </a>",
"      promotes sleep and weight gain and may also be a useful alternative. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Fatigue'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Similarly, several agents can be considered in patients with predominant symptoms of pain, insomnia, anorexia or irritability.",
"     </li>",
"     <li>",
"      In patients whose predominant symptom is insomnia, we provide advice on good sleep hygiene. In non-responding patients, we suggest a non-benzodiazepine hypnotic (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/48/13064?source=see_link\">",
"       zolpidem",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/24/17798?source=see_link\">",
"       zopiclone",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). As an alternative, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"       trazodone",
"      </a>",
"      , a sleep promoting antidepressant, which is safe, frequently effective across a wide dosage range (ie, 25 to 150 mg) and is especially useful for patients with abuse potential who require long-term treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Insomnia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients whose predominant symptoms are aches and pains, we suggest a combined serotonin-norepinephrine reuptake inhibitor (SNRI) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Combined serotonin-norepinephrine reuptake inhibitors available in the United States include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/33/18967?source=see_link\">",
"       desvenlafaxine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      . However, the Food and Drug Administration has issued a precaution about the use of duloxetine in patients with chronic liver disease and thus it is probably not a good choice. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Aches and pains'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antidepressants with both norepinephrine and serotonin activity (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      ) may be more effective than SRIs in the treatment of pain and may be agents of choice for patients who present with significant pain complaints.",
"     </li>",
"     <li>",
"      In patients who develop irritability, we suggest either a SRI or SNRI (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Irritability'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A small percentage of patients receiving antiviral therapy develop mania, which should be considered a clinical emergency. In such cases, antidepressants should be stopped and an immediate psychiatric referral arranged. Agents effective for manic symptoms include antipsychotics and mood stabilizers. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Mania'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Suicide is a real possibility for patients who develop neuropsychiatric side effects during therapy. Risk for this should be assessed at every evaluation. Patients who develop suicidal ideation require immediate psychiatric evaluation. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Suicidal ideation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/1\">",
"      Rifai MA, Loftis JM, Hauser P. Interferon-alpha treatment of patients with Hepatitis C: the role of a comprehensive risk-benefit assessment. CNS Drugs 2005; 19:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/2\">",
"      Knott A, Dieperink E, Willenbring ML, et al. Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol 2006; 101:2254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/3\">",
"      Schaefer M, Hinzpeter A, Mohmand A, et al. Hepatitis C treatment in \"difficult-to-treat\" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology 2007; 46:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/4\">",
"      Raison CL, Woolwine BJ, Demetrashvili MF, et al. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther 2007; 25:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/5\">",
"      Nelligan JA, Loftis JM, Matthews AM, et al. Depression comorbidity and antidepressant use in veterans with chronic hepatitis C: results from a retrospective chart review. J Clin Psychiatry 2008; 69:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/6\">",
"      Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 344:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/7\">",
"      Schaefer M, Schwaiger M, Garkisch AS, et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005; 42:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/8\">",
"      Kraus MR, Sch&auml;fer A, Al-Taie O, Scheurlen M. Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepat 2005; 12:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/9\">",
"      Morasco BJ, Rifai MA, Loftis JM, et al. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J Affect Disord 2007; 103:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/10\">",
"      McNutt MD, Liu S, Manatunga A, et al. Neurobehavioral effects of interferon-&alpha; in patients with hepatitis-C: symptom dimensions and responsiveness to paroxetine. Neuropsychopharmacology 2012; 37:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/11\">",
"      de Knegt RJ, Bezemer G, Van Gool AR, et al. Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C. Aliment Pharmacol Ther 2011; 34:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/12\">",
"      Schaefer M, Sarkar R, Knop V, et al. Escitalopram for the prevention of peginterferon-&alpha;2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. Ann Intern Med 2012; 157:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/13\">",
"      Maddock C, Baita A, Orr&ugrave; MG, et al. Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms. J Psychopharmacol 2004; 18:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/14\">",
"      Kraus MR, Sch&auml;fer A, Faller H, et al. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002; 16:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/15\">",
"      Horikawa N, Yamazaki T, Izumi N, Uchihara M. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. Gen Hosp Psychiatry 2003; 25:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/16\">",
"      Kraus MR, Sch&auml;fer A, Faller H, et al. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 2003; 64:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/17\">",
"      Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002; 7:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/18\">",
"      Sch&auml;fer M, Schmidt F, Amann B, et al. Adding low-dose antidepressants to interferon alpha treatment for chronic hepatitis C improved psychiatric tolerability in a patient with schizoaffective psychosis. Neuropsychobiology 2000; 42 Suppl 1:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/19\">",
"      Farah A. Interferon-induced depression treated with citalopram. J Clin Psychiatry 2002; 63:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/20\">",
"      Gleason OC, Yates WR. Five cases of interferon-alpha-induced depression treated with antidepressant therapy. Psychosomatics 1999; 40:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/21\">",
"      Gleason OC, Yates WR, Isbell MD, Philipsen MA. An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry 2002; 63:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/22\">",
"      Levenson JL, Fallon HJ. Fluoxetine treatment of depression caused by interferon-alpha. Am J Gastroenterol 1993; 88:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/23\">",
"      Schramm TM, Lawford BR, Macdonald GA, Cooksley WG. Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust 2000; 173:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/24\">",
"      Yoshida K, Higuchi H, Takahashi H, Shimizu T. Favorable effect of milnacipran on depression induced by interferon-alpha. J Neuropsychiatry Clin Neurosci 2003; 15:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/25\">",
"      Kraus MR, Sch&auml;fer A, Sch&ouml;ttker K, et al. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut 2008; 57:531.",
"     </a>",
"    </li>",
"    <li>",
"     Diagnostic and statistical manual of mental disorders: DSM-IV--4th ed., American Psychiatric Association, Washington, DC 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/27\">",
"      Kraus MR, Sch&auml;fer A, Scheurlen M. Paroxetine for the prevention of depression induced by interferon alfa. N Engl J Med 2001; 345:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/28\">",
"      Hauser P, Soler R, Reed S, et al. Prophylactic treatment of depression induced by interferon-alpha. Psychosomatics 2000; 41:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/29\">",
"      Schaefer, M, Schwaiger, M, Berg, T. Citalopram for the prevention of interferon-alpha associated depression in psychiatric risk patients (abstract). Hepatology 2003; 38:320A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/30\">",
"      Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/31\">",
"      Van Thiel DH, Friedlander L, De Maria N, et al. Treatment of chronic hepatitis C in individuals with pre-existing or confounding neuropsychiatric disease. Hepatogastroenterology 1998; 45:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/32\">",
"      Diez-Quevedo C, Masnou H, Planas R, et al. Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011; 72:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/33\">",
"      Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992; 326:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/34\">",
"      Malani AK, Ammar H. Medical management of depression. N Engl J Med 2006; 354:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/35\">",
"      Hirschfeld RM, Montgomery SA, Aguglia E, et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry 2002; 63:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/36\">",
"      Capuron L, Gumnick JF, Musselman DL, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002; 26:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/37\">",
"      Morrow GR, Hickok JT, Roscoe JA, et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol 2003; 21:4635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/38\">",
"      Greco T, Eckert G, Kroenke K. The outcome of physical symptoms with treatment of depression. J Gen Intern Med 2004; 19:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/39\">",
"      Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004; 126:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/40\">",
"      Pockros PJ, Shiffman ML, Schiff ER, et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 2004; 40:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/41\">",
"      Schwartz AL, Thompson JA, Masood N. Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate. Oncol Nurs Forum 2002; 29:E85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/42\">",
"      Sugawara Y, Akechi T, Shima Y, et al. Efficacy of methylphenidate for fatigue in advanced cancer patients: a preliminary study. Palliat Med 2002; 16:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/43\">",
"      Sarhill N, Walsh D, Nelson KA, et al. Methylphenidate for fatigue in advanced cancer: a prospective open-label pilot study. Am J Hosp Palliat Care 2001; 18:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/44\">",
"      Jones EA. Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy. Lancet 1999; 354:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/45\">",
"      Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 2005; 52:2495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/46\">",
"      Quarantini LC, Miranda-Scippa A, Schinoni MI, et al. Effect of amantadine on depressive symptoms in chronic hepatitis C patients treated with pegylated interferon: a randomized, controlled pilot study. Clin Neuropharmacol 2006; 29:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/47\">",
"      Simon GE, VonKorff M, Piccinelli M, et al. An international study of the relation between somatic symptoms and depression. N Engl J Med 1999; 341:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/48\">",
"      Wichers MC, Koek GH, Robaeys G, et al. Early increase in vegetative symptoms predicts IFN-alpha-induced cognitive-depressive changes. Psychol Med 2005; 35:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/49\">",
"      Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005; 6:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/50\">",
"      Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005; 119:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/51\">",
"      Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005; 116:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/52\">",
"      Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004; 50:2974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/53\">",
"      Fava M, Mallinckrodt CH, Detke MJ, et al. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J Clin Psychiatry 2004; 65:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/54\">",
"      Yucel A, Ozyalcin S, Koknel Talu G, et al. The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study. Eur J Pain 2005; 9:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/55\">",
"      Ozyalcin SN, Talu GK, Kiziltan E, et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 2005; 45:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/56\">",
"      Guldiken S, Guldiken B, Arikan E, et al. Complete relief of pain in acute painful diabetic neuropathy of rapid glycaemic control (insulin neuritis) with venlafaxine HCL. Diabetes Nutr Metab 2004; 17:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/57\">",
"      Bulut S, Berilgen MS, Baran A, et al. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg 2004; 107:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/58\">",
"      Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004; 110:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/59\">",
"      Forssell H, Tasmuth T, Tenovuo O, et al. Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial. J Orofac Pain 2004; 18:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/60\">",
"      Semenchuk MR, Sherman S, Davis B. Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology 2001; 57:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/61\">",
"      Semenchuk MR, Davis B. Efficacy of sustained-release bupropion in neuropathic pain: an open-label study. Clin J Pain 2000; 16:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/62\">",
"      Freynhagen R, Muth-Selbach U, Lipfert P, et al. The effect of mirtazapine in patients with chronic pain and concomitant depression. Curr Med Res Opin 2006; 22:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/63\">",
"      Bendtsen L, Jensen R. Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache. Neurology 2004; 62:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/64\">",
"      Constant A, Castera L, Dantzer R, et al. Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiatry 2005; 66:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/40/1674/abstract/65\">",
"      Altshuler LL, Post RM, Leverich GS, et al. Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry 1995; 152:1130.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4857 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-71A5527948-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_40_1674=[""].join("\n");
var outline_f1_40_1674=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PSYCHOSOCIAL CONTEXT OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      WHO CAN BE SAFELY TREATED WITH INTERFERON",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      WHEN TO TREAT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DEPRESSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      FATIGUE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INSOMNIA, PAIN, ANOREXIA AND IRRITABILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Insomnia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Aches and pains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Anorexia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Irritability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MANIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      HOW LONG SHOULD TREATMENT LAST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUICIDAL IDEATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      IFN-alfa in patients with psychiatric illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/4857\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/4857|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?12/56/13187\" title=\"algorithm 1\">",
"      Rx psych side effects IFN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/4857|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/14/28907\" title=\"table 1\">",
"      Mania versus depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/49/18203\" title=\"table 2\">",
"      Strategies rx depression IFN",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10007?source=related_link\">",
"      Management of pain in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41337?source=related_link\">",
"      Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24551?source=related_link\">",
"      Neuropsychiatric side effects associated with interferon-alfa plus ribavirin therapy: Recognition and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/4/17478?source=related_link\">",
"      Patient information: Hepatitis C (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_40_1675="Sexually transmitted diseases and travel";
var content_f1_40_1675=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sexually transmitted infections causing fever and systemic symptoms",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Syphilis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Disseminated gonococcal infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Primary HIV-1 infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hepatitis B",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cytomegalovirus infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hepatitis A (oral-anal)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hepatitis C (rare sexual transmission)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Epstein-Barr virus",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_40_1675=[""].join("\n");
var outline_f1_40_1675=null;
var title_f1_40_1676="Portals of entry for fusariosis";
var content_f1_40_1676=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Portals of entry for fusariosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Airborne",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Immunocompetent host",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Keratitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sinusitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Immunocompromised host",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sinusitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Disseminated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Direct contact",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Immunocompetent host",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Onychomycosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cutaneous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Peritonitis (CAPD catheter)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Thrombophlebitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Keratitis (traumatic inoculation, contaminated contact lens solution)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Immunocompromised host",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cellulitis at site of onychomycosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Arthritis at sites of cutaneous damage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Osteomyelitis at sites of cutaneous damage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bloodstream infection and cellulitis at central venous catheter site",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Disseminated",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CAPD: continuous ambulatory peritoneal dialysis.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_40_1676=[""].join("\n");
var outline_f1_40_1676=null;
var title_f1_40_1677="Causes of hematospermia";
var content_f1_40_1677=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F64639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F64639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Abnormalities reported in patients with hematospermia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chlamydia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytomegalovirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enterococcus fecalis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Herpex Simplex Virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Schistosomiasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trichomoniasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tuberculosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ureaplasma urealyticum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Malignant tumors (urogenital)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bladder cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prostate adenocarcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prostate sarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Testicular tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Malignant tumors (metastatic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Melanoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal call carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Prostatic disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benign prostatic hypertrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prostatic calculi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prostatic telangiectasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prostatic urethral hemangiomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prostatic urethral polyps",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prostatic utricle (or mullerian duct) cysts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prostatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Seminal vesicle disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adenomyosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amyloidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calculi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cysts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dilated seminal vesicles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ectopic prostate tissue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Spermatic cord and ejaculatory system disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cavernous hemangiomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ejaculation duct obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epididymitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Urethral disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ectopic prostate tissue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Papillary urethritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Vascular disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Genitourinary varices",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignant hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Congenital or drug-induced bleeding disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aspirin therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prothrombin deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        von Willebrand disease",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_40_1677=[""].join("\n");
var outline_f1_40_1677=null;
var title_f1_40_1678="Hand-sewn ileocolic anastomosis - two layer closur anterior wall";
var content_f1_40_1678=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F76648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F76648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hand-sewn ileocolic anastomosis - two layer closure anterior wall",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 265px; height: 244px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Connell sutures are used on the anterior wall of the anastomosis between the ileum and colon.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_40_1678=[""].join("\n");
var outline_f1_40_1678=null;
var title_f1_40_1679="Management Brugada syndrome-II";
var content_f1_40_1679=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 526px\">",
"   <div class=\"ttl\">",
"    Management of patients with Brugada syndrome according to baseline ECG and symptoms-II",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 506px; height: 329px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Class I designation indicates clear evidence that the procedure or treatment is useful or effective; Class II, conflicting evidence about usefulness or efficacy; Class IIa, weight of evidence is in favor of usefulness or efficacy; and Class IIb, usefulness or efficacy is less well established.",
"    <div class=\"footnotes\">",
"     BS: Brugada syndrome; NAR: nocturnal agonal respiration; and SCD: sudden cardiac death.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005; 111:659. Copyright &copy; 2005 Lippincott Williams and Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_40_1679=[""].join("\n");
var outline_f1_40_1679=null;
